BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed FDA decision calendar
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:fe934e9e84220d4b2e6a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261119
DTEND;VALUE=DATE:20261120
SUMMARY:ADCOM (scheduled): AdCom 2026-11-19: Microbiology Devices Panel of 
 the Medical Devices Advisory Committee
DESCRIPTION:AdCom 2026-11-19: Microbiology Devices Panel of the Medical Dev
 ices Advisory Committee\nConfidence: scheduled\nSource: https://www.federa
 lregister.gov/documents/2026/09/16/2026-18920/microbiology-devices-panel-o
 f-the-medical-devices-advisory-committee-notice-of-meeting-establishment\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.federalregister.gov/documents/2026/09/16/2026-18920/microbi
 ology-devices-panel-of-the-medical-devices-advisory-committee-notice-of-me
 eting-establishment
CATEGORIES:adcom,scheduled
END:VEVENT
BEGIN:VEVENT
UID:e55165b575de859a6c6c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261122
DTEND;VALUE=DATE:20261123
SUMMARY:CAPR PDUFA (company-disclosed): PDUFA November 22\, 2026 - CAPRICOR
  THERAPEUTICS\, INC.
DESCRIPTION:PDUFA November 22\, 2026 - CAPRICOR THERAPEUTICS\, INC.\nConfid
 ence: company-disclosed\nTicker CAPR (confidence 1.0)\nSource: https://www
 .sec.gov/Archives/edgar/data/1133869/000110465926125150/capr-ex99d1.htm\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1133869/000110465926125150/capr
 -ex99d1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:c964f0c4758fe068992b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261127
DTEND;VALUE=DATE:20261128
SUMMARY:BBIO PDUFA (company-disclosed): PDUFA November 27\, 2026 - BridgeBi
 o Pharma\, Inc.
DESCRIPTION:PDUFA November 27\, 2026 - BridgeBio Pharma\, Inc.\nConfidence:
  company-disclosed\nTicker BBIO (confidence 1.0)\nSource: https://www.sec.
 gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm
 \nScheduling/reference data from public records\; dates can move. Not inve
 stment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio
 -20260930xex991.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:a0f06b3d1c83a3223745@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:COGT PDUFA (company-disclosed): bezuclastinib
DESCRIPTION:PDUFA November 30\, 2026 - Cogent Biosciences\, Inc. (bezuclast
 inib)\nConfidence: company-disclosed\nTicker COGT (confidence 1.0)\nSource
 : https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-
 ex99_1.htm\nScheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt
 -ex99_1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:8946f5a6563b86f9d7dc@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:ANAB PDUFA (company-disclosed): imsidolimab
DESCRIPTION:PDUFA Dec. 12\, 2026 - ANAPTYSBIO\, INC (imsidolimab)\nConfiden
 ce: company-disclosed\nTicker ANAB (confidence 1.0)\nSource: https://www.s
 ec.gov/Archives/edgar/data/1370053/000119312526396690/anab-ex99_1.htm\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1370053/000119312526396690/anab
 -ex99_1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:f6b2e9cda2fe8dfb571e@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:VNDA PDUFA (company-disclosed): imsidolimab
DESCRIPTION:PDUFA December 12\, 2026 - Vanda Pharmaceuticals Inc. (imsidoli
 mab)\nConfidence: company-disclosed\nTicker VNDA (confidence 1.0)\nSource:
  https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda8-
 k852026exhibit991.htm\nScheduling/reference data from public records\; dat
 es can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda
 8-k852026exhibit991.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:cf78e8dd472f8adc6439@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:MLYS PDUFA (company-disclosed): lorundrostat
DESCRIPTION:PDUFA December 22\, 2026 - Mineralys Therapeutics\, Inc. (lorun
 drostat)\nConfidence: company-disclosed\nTicker MLYS (confidence 1.0)\nSou
 rce: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000142/ml
 ys2026q38kex991.htm\nScheduling/reference data from public records\; dates
  can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1933414/000193341426000142/mlys
 2026q38kex991.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:1363807714957010cc9c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:PRAX PDUFA (company-disclosed): ulixacaltamide
DESCRIPTION:PDUFA December 27\, 2026 - Praxis Precision Medicines\, Inc. (u
 lixacaltamide)\nConfidence: company-disclosed\nTicker PRAX (confidence 1.0
 )\nSource: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000
 086/praxisq32026pr.htm\nScheduling/reference data from public records\; da
 tes can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1689548/000168954826000086/prax
 isq32026pr.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:9e2ec8e40c40b33e01b9@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:BHVN PDUFA (company-disclosed): PDUFA first quarter of 2027 - Bioha
 ven Ltd.
DESCRIPTION:PDUFA first quarter of 2027 - Biohaven Ltd.\nConfidence: compan
 y-disclosed\nDate precision: quarter (shown on the first day)\nTicker BHVN
  (confidence 1.0)\nSource: https://www.sec.gov/Archives/edgar/data/1935979
 /000193597926000083/bhvn-20261022.htm\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1935979/000193597926000083/bhvn
 -20261022.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:2d23735e8a66f9af6a3e@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:CRMD PDUFA (company-disclosed): PDUFA Q1 2027 - CorMedix Inc.
DESCRIPTION:PDUFA Q1 2027 - CorMedix Inc.\nConfidence: company-disclosed\nD
 ate precision: quarter (shown on the first day)\nTicker CRMD (confidence 1
 .0)\nSource: https://www.sec.gov/Archives/edgar/data/1410098/0001213900261
 10477/ea030895701ex99-1.htm\nScheduling/reference data from public records
 \; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1410098/000121390026110477/ea03
 0895701ex99-1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:7e8245ec90dc30820104@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:DYN PDUFA (company-disclosed): rostudirsen
DESCRIPTION:PDUFA January 21\, 2027 - Dyne Therapeutics\, Inc. (rostudirsen
 )\nConfidence: company-disclosed\nTicker DYN (confidence 1.0)\nSource: htt
 ps://www.sec.gov/Archives/edgar/data/1818794/000181879426000013/dyn-ex99_1
 .htm\nScheduling/reference data from public records\; dates can move. Not 
 investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1818794/000181879426000013/dyn-
 ex99_1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:4e83bcab93085d3c5335@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:ANAB PDUFA (company-disclosed): PDUFA February 2027 - ANAPTYSBIO\, 
 INC
DESCRIPTION:PDUFA February 2027 - ANAPTYSBIO\, INC\nConfidence: company-dis
 closed\nDate precision: month (shown on the first day)\nTicker ANAB (confi
 dence 1.0)\nSource: https://www.sec.gov/Archives/edgar/data/1370053/000119
 312526396690/anab-ex99_1.htm\nScheduling/reference data from public record
 s\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1370053/000119312526396690/anab
 -ex99_1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:d5dac277c40e8a4c6933@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:APMD PDUFA (company-disclosed): PDUFA February 28\, 2027 - Apnimed\
 , Inc.
DESCRIPTION:PDUFA February 28\, 2027 - Apnimed\, Inc.\nConfidence: company-
 disclosed\nTicker APMD (confidence 1.0)\nSource: https://www.sec.gov/Archi
 ves/edgar/data/1745648/000119312526462171/apmd-ex99_1.htm\nScheduling/refe
 rence data from public records\; dates can move. Not investment\, legal or
  medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1745648/000119312526462171/apmd
 -ex99_1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:0c985e199b365bf84e37@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:PVLA PDUFA (company-disclosed): PDUFA February 28\, 2027 - PALVELLA
  THERAPEUTICS\, INC.
DESCRIPTION:PDUFA February 28\, 2027 - PALVELLA THERAPEUTICS\, INC.\nConfid
 ence: company-disclosed\nTicker PVLA (confidence 1.0)\nSource: https://www
 .sec.gov/Archives/edgar/data/1583648/000119312526448594/pvla-ex99_2.htm\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1583648/000119312526448594/pvla
 -ex99_2.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:526e3fa9d3fd9b7e35cd@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270310
DTEND;VALUE=DATE:20270311
SUMMARY:NTLA PDUFA (company-disclosed): PDUFA MARCH 10\, 2027 - Intellia Th
 erapeutics\, Inc.
DESCRIPTION:PDUFA MARCH 10\, 2027 - Intellia Therapeutics\, Inc.\nConfidenc
 e: company-disclosed\nTicker NTLA (confidence 1.0)\nSource: https://www.se
 c.gov/Archives/edgar/data/1652130/000119312526460948/ntla-ex99_1.htm\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1652130/000119312526460948/ntla
 -ex99_1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:3dbf6886137afdd01452@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270316
DTEND;VALUE=DATE:20270317
SUMMARY:AQST PDUFA (company-disclosed): PDUFA March 16\, 2027 - Aquestive T
 herapeutics\, Inc.
DESCRIPTION:PDUFA March 16\, 2027 - Aquestive Therapeutics\, Inc.\nConfiden
 ce: company-disclosed\nTicker AQST (confidence 1.0)\nSource: https://www.s
 ec.gov/Archives/edgar/data/1398733/000139873326000079/jefferiesglobalhealt
 hcar.htm\nScheduling/reference data from public records\; dates can move. 
 Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1398733/000139873326000079/jeff
 eriesglobalhealthcar.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:302b28e85809c323be25@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270325
DTEND;VALUE=DATE:20270326
SUMMARY:UNCY PDUFA (company-disclosed): PDUFA March 25\, 2027 - Unicycive T
 herapeutics\, Inc.
DESCRIPTION:PDUFA March 25\, 2027 - Unicycive Therapeutics\, Inc.\nConfiden
 ce: company-disclosed\nTicker UNCY (confidence 1.0)\nSource: https://www.s
 ec.gov/Archives/edgar/data/1766140/000121390026120261/ea031236501ex99-1.ht
 m\nScheduling/reference data from public records\; dates can move. Not inv
 estment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1766140/000121390026120261/ea03
 1236501ex99-1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:6e647fe5deded62fc726@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:ATRA PDUFA (company-disclosed): PDUFA March 31\, 2027 - Atara Bioth
 erapeutics\, Inc.
DESCRIPTION:PDUFA March 31\, 2027 - Atara Biotherapeutics\, Inc.\nConfidenc
 e: company-disclosed\nTicker ATRA (confidence 1.0)\nSource: https://www.se
 c.gov/Archives/edgar/data/1604464/000110465926125171/tmb-ex99d1.htm\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1604464/000110465926125171/tmb-
 ex99d1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:df950432cfc4c316e801@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:HRMY PDUFA (company-disclosed): PDUFA April 1\, 2027 - Harmony Bios
 ciences Holdings\, Inc.
DESCRIPTION:PDUFA April 1\, 2027 - Harmony Biosciences Holdings\, Inc.\nCon
 fidence: company-disclosed\nTicker HRMY (confidence 1.0)\nSource: https://
 www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy-ex99d1.htm
 \nScheduling/reference data from public records\; dates can move. Not inve
 stment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy
 -ex99d1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:e5708a7e335b6b9fe101@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270414
DTEND;VALUE=DATE:20270415
SUMMARY:INBX PDUFA (company-disclosed): PDUFA April 14\, 2027 - Inhibrx Bio
 sciences\, Inc.
DESCRIPTION:PDUFA April 14\, 2027 - Inhibrx Biosciences\, Inc.\nConfidence:
  company-disclosed\nTicker INBX (confidence 1.0)\nSource: https://www.sec.
 gov/Archives/edgar/data/2007919/000200791926000033/inhibrx-20260615.htm\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/inhi
 brx-20260615.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:36071142b7f2ae81a033@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:QURE PDUFA (company-disclosed): ifezuntirgene
DESCRIPTION:PDUFA May 1\, 2027 - uniQure N.V. (ifezuntirgene)\nConfidence: 
 company-disclosed\nTicker QURE (confidence 1.0)\nSource: https://www.sec.g
 ov/Archives/edgar/data/1590560/000110465926120915/tm2628699d1_ex99-1.htm\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1590560/000110465926120915/tm26
 28699d1_ex99-1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:5b028eed19e20fbdee33@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:AXSM PDUFA (company-disclosed): PDUFA May 1\, 2027 - Axsome Therape
 utics\, Inc.
DESCRIPTION:PDUFA May 1\, 2027 - Axsome Therapeutics\, Inc.\nConfidence: co
 mpany-disclosed\nTicker AXSM (confidence 1.0)\nSource: https://www.sec.gov
 /Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm\nSchedulin
 g/reference data from public records\; dates can move. Not investment\, le
 gal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm
 -ex99_1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:c26a5dfd8485b62cc112@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:RFL PDUFA (company-disclosed): PDUFA June 2027 - Rafael Holdings\, 
 Inc.
DESCRIPTION:PDUFA June 2027 - Rafael Holdings\, Inc.\nConfidence: company-d
 isclosed\nDate precision: month (shown on the first day)\nTicker RFL (conf
 idence 1.0)\nSource: https://www.sec.gov/Archives/edgar/data/1713863/00012
 1390026117552/ea031154001ex99-1.htm\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1713863/000121390026117552/ea03
 1154001ex99-1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:467b48df6af8afe9a570@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270614
DTEND;VALUE=DATE:20270615
SUMMARY:URGN PDUFA (company-disclosed): PDUFA June 14\, 2027 - UroGen Pharm
 a Ltd.
DESCRIPTION:PDUFA June 14\, 2027 - UroGen Pharma Ltd.\nConfidence: company-
 disclosed\nTicker URGN (confidence 1.0)\nSource: https://www.sec.gov/Archi
 ves/edgar/data/1668243/000143774926034769/ex_1036873.htm\nScheduling/refer
 ence data from public records\; dates can move. Not investment\, legal or 
 medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1668243/000143774926034769/ex_1
 036873.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:afee2ac9507c5b661bf9@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:BBIO PDUFA (company-disclosed): infigratinib
DESCRIPTION:PDUFA first half of 2028 - BridgeBio Pharma\, Inc. (infigratini
 b)\nConfidence: company-disclosed\nDate precision: half (shown on the firs
 t day)\nTicker BBIO (confidence 1.0)\nSource: https://www.sec.gov/Archives
 /edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm\nScheduling
 /reference data from public records\; dates can move. Not investment\, leg
 al or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio
 -20260930xex991.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:efdf374084eeeb204ad0@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:SMMT CRL: AK112/SMT112 (also referred to by the Applicant as ivones
 cimab)
DESCRIPTION:CRL 2026-11-13: Summit Therapeutics Inc. BLA 761524 (AK112/SMT1
 12 (also referred to by the Applicant as ivonescimab))\nConfidence: confir
 med\nTicker SMMT (confidence 0.9)\nSource: https://download.open.fda.gov/c
 rl/CRL_BLA761524_20261113.pdf\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_BLA761524_20261113.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:b0f487abde6314630780@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:TEVA APPROVAL: IGALMI
DESCRIPTION:Approved 2026-11-13: IGALMI (NDA215390 SUPPL3)\nConfidence: con
 firmed\nTicker TEVA (confidence 0.6)\nSource: https://www.accessdata.fda.g
 ov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215390\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215390
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:83e5f62f55129fafcaa9@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:GENENTECH APPROVAL: GAZYVA
DESCRIPTION:Approved 2026-11-13: GAZYVA (BLA125486 SUPPL44)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=125486\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=125486
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:7f556f922d7447ac9f94@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:AZN APPROVAL: IMFINZI
DESCRIPTION:Approved 2026-11-13: IMFINZI (BLA761069 SUPPL59)\nConfidence: c
 onfirmed\nTicker AZN (confidence 0.6)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761069
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:5eb806f20095efe01cd2@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:ALEXION PHARM APPROVAL: KLYGEFA
DESCRIPTION:Approved 2026-11-13: KLYGEFA (BLA761488 ORIG1)\nConfidence: con
 firmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?
 event=overview.process&ApplNo=761488\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761488
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:1458d3658db41b4a697e@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:CYTK APPROVAL: MYQORZO
DESCRIPTION:Approved 2026-11-13: MYQORZO (NDA219083 SUPPL2)\nConfidence: co
 nfirmed\nTicker CYTK (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219083\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=219083
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:71adc9e259d6a31434e7@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:BIIB APPROVAL: ZURZUVAE
DESCRIPTION:Approved 2026-11-13: ZURZUVAE (NDA217369 SUPPL4)\nConfidence: c
 onfirmed\nTicker BIIB (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217369\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=217369
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:ed6db8fc459171db4988@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:BIOCON BIOLOGICS INC APPROVAL: PEBRILZO
DESCRIPTION:Approved 2026-11-12: PEBRILZO (BLA761501 ORIG1)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=761501\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761501
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:78ebe032734581caf4c5@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:EMD SERONO APPROVAL: PIMJETMI
DESCRIPTION:Approved 2026-11-10: PIMJETMI (NDA220414 ORIG1)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=220414\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220414
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:42d748c50c3d3d44bee0@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:CMG PHARM CO LTD APPROVAL: MEZOFY
DESCRIPTION:Approved 2026-11-10: MEZOFY (NDA211448 SUPPL1)\nConfidence: con
 firmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?
 event=overview.process&ApplNo=211448\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=211448
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:97f150108a5fb070ec5f@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:AVYXA HOLDINGS APPROVAL: OXDERYS
DESCRIPTION:Approved 2026-11-09: OXDERYS (NDA221093 ORIG1)\nConfidence: con
 firmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?
 event=overview.process&ApplNo=221093\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=221093
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:a47a73fd5477cdd424e5@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:BAYER HEALTHCARE APPROVAL: SUNHARBO
DESCRIPTION:Approved 2026-11-09: SUNHARBO (NDA221291 ORIG1)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=221291\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=221291
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:349bb1e736e154f63bbf@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:FMS APPROVAL: MULTIBIC
DESCRIPTION:Approved 2026-11-09: MULTIBIC (NDA219457 ORIG1)\nConfidence: co
 nfirmed\nTicker FMS (confidence 0.6)\nSource: https://www.accessdata.fda.g
 ov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219457\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=219457
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:37432abc83a7859ac6ca@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:IMNM PDUFA (company-disclosed): PDUFA November 9\, 2026 - Immunome 
 Inc.
DESCRIPTION:PDUFA November 9\, 2026 - Immunome Inc.\nConfidence: company-di
 sclosed\nTicker IMNM (confidence 1.0)\nSource: https://www.sec.gov/Archive
 s/edgar/data/1472012/000119312526453556/imnm-ex99_1.htm\nScheduling/refere
 nce data from public records\; dates can move. Not investment\, legal or m
 edical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1472012/000119312526453556/imnm
 -ex99_1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:c29822059b3455457ee1@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261105
DTEND;VALUE=DATE:20261106
SUMMARY:JANSSEN BIOTECH APPROVAL: RYBREVANT FASPRO
DESCRIPTION:Approved 2026-11-05: RYBREVANT FASPRO (BLA761433 SUPPL2)\nConfi
 dence: confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/
 index.cfm?event=overview.process&ApplNo=761433\nScheduling/reference data 
 from public records\; dates can move. Not investment\, legal or medical ad
 vice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761433
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:7419082befd4a75f488a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261101
DTEND;VALUE=DATE:20261102
SUMMARY:MLTX PDUFA (company-disclosed): PDUFA November 2026 - MoonLake Immu
 notherapeutics
DESCRIPTION:PDUFA November 2026 - MoonLake Immunotherapeutics\nConfidence: 
 company-disclosed\nDate precision: month (shown on the first day)\nTicker 
 MLTX (confidence 1.0)\nSource: https://www.sec.gov/Archives/edgar/data/182
 1586/000121390026070362/ea029539901ex99-1.htm\nScheduling/reference data f
 rom public records\; dates can move. Not investment\, legal or medical adv
 ice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1821586/000121390026070362/ea02
 9539901ex99-1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:dde017f1458e198adf3d@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261030
DTEND;VALUE=DATE:20261031
SUMMARY:Sydnexis ADCOM (scheduled): AdCom 2026-10-30: Dermatologic and Opht
 halmic Drugs Advisory Committee - NDA 219694
DESCRIPTION:AdCom 2026-10-30: Dermatologic and Ophthalmic Drugs Advisory Co
 mmittee - NDA 219694\nConfidence: scheduled\nSource: https://www.federalre
 gister.gov/documents/2026/09/25/2026-19700/dermatologic-and-ophthalmic-dru
 gs-advisory-committee-notice-of-meeting-establishment-of-a-public\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.federalregister.gov/documents/2026/09/25/2026-19700/dermato
 logic-and-ophthalmic-drugs-advisory-committee-notice-of-meeting-establishm
 ent-of-a-public
CATEGORIES:adcom,scheduled
END:VEVENT
BEGIN:VEVENT
UID:3dc4cc2a7007f0f085a5@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261030
DTEND;VALUE=DATE:20261031
SUMMARY:INO PDUFA (company-disclosed): PDUFA October 30\, 2026 - INOVIO PHA
 RMACEUTICALS\, INC.
DESCRIPTION:PDUFA October 30\, 2026 - INOVIO PHARMACEUTICALS\, INC.\nConfid
 ence: company-disclosed\nTicker INO (confidence 1.0)\nSource: https://www.
 sec.gov/Archives/edgar/data/1055726/000105572626000024/ino-63026x8kex991.h
 tm\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1055726/000105572626000024/ino-
 63026x8kex991.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:0acde661bcdf80e56b9a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261029
DTEND;VALUE=DATE:20261030
SUMMARY:AVYXA HOLDINGS APPROVAL: AXYCIS
DESCRIPTION:Approved 2026-10-29: AXYCIS (NDA220748 ORIG1)\nConfidence: conf
 irmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?e
 vent=overview.process&ApplNo=220748\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220748
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:481f39856b2789694fdf@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261029
DTEND;VALUE=DATE:20261030
SUMMARY:SUN PHARMA GLOBAL APPROVAL: ILUMYA
DESCRIPTION:Approved 2026-10-29: ILUMYA (BLA761067 SUPPL31)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=761067\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761067
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:09e113bbc1a089d9df75@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261027
DTEND;VALUE=DATE:20261028
SUMMARY:XBRANE BIOPHARMA AB APPROVAL: LUCAMZI
DESCRIPTION:Approved 2026-10-27: LUCAMZI (BLA761187 ORIG1)\nConfidence: con
 firmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?
 event=overview.process&ApplNo=761187\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761187
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:ef114689b9b1673837aa@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261026
DTEND;VALUE=DATE:20261027
SUMMARY:PFE APPROVAL: TALZENNA
DESCRIPTION:Approved 2026-10-26: TALZENNA (NDA217439 SUPPL4)\nConfidence: c
 onfirmed\nTicker PFE (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217439\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=217439
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:6c16a678184c1a0542d8@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261026
DTEND;VALUE=DATE:20261027
SUMMARY:PFE APPROVAL: TALZENNA
DESCRIPTION:Approved 2026-10-26: TALZENNA (NDA211651 SUPPL14)\nConfidence: 
 confirmed\nTicker PFE (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=211651
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:9fdc486f96454b05e8e9@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261023
DTEND;VALUE=DATE:20261024
SUMMARY:PHARMACOSMOS APPROVAL: MONOFERRIC
DESCRIPTION:Approved 2026-10-23: MONOFERRIC (NDA208171 SUPPL6)\nConfidence:
  confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.
 cfm?event=overview.process&ApplNo=208171\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=208171
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:ea40eba7fb9c4ce3c927@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261023
DTEND;VALUE=DATE:20261024
SUMMARY:NVO APPROVAL: AWIQLI FLEXTOUCH
DESCRIPTION:Approved 2026-10-23: AWIQLI FLEXTOUCH (BLA761326 SUPPL1)\nConfi
 dence: confirmed\nTicker NVO (confidence 0.95)\nSource: https://www.access
 data.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=7613
 26\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761326
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:1ad6806cdfe7e8902280@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261023
DTEND;VALUE=DATE:20261024
SUMMARY:ABBV APPROVAL: SKYRIZI
DESCRIPTION:Approved 2026-10-23: SKYRIZI (BLA761105 SUPPL53)\nConfidence: c
 onfirmed\nTicker ABBV (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761105\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761105
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:50ab17ca9fafc44132a3@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261022
DTEND;VALUE=DATE:20261023
SUMMARY:AMGN APPROVAL: PAVBLU
DESCRIPTION:Approved 2026-10-22: PAVBLU (BLA761298 ORIG2)\nConfidence: conf
 irmed\nTicker AMGN (confidence 0.9)\nSource: https://www.accessdata.fda.go
 v/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761298\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761298
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:df0ee68016a30f140b8d@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261022
DTEND;VALUE=DATE:20261023
SUMMARY:FORMYCON AG APPROVAL: AHZANTIVE
DESCRIPTION:Approved 2026-10-22: AHZANTIVE (BLA761378 ORIG2)\nConfidence: c
 onfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cf
 m?event=overview.process&ApplNo=761378\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761378
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:272f38a324c904704225@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261022
DTEND;VALUE=DATE:20261023
SUMMARY:SANDOZ INC APPROVAL: ENZEEVU
DESCRIPTION:Approved 2026-10-22: ENZEEVU (BLA761382 ORIG2)\nConfidence: con
 firmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?
 event=overview.process&ApplNo=761382\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761382
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:33b4e08b9173eb3b6b54@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261021
DTEND;VALUE=DATE:20261022
SUMMARY:ALEXION PHARM APPROVAL: ULTOMIRIS
DESCRIPTION:Approved 2026-10-21: ULTOMIRIS (BLA761108 SUPPL46)\nConfidence:
  confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.
 cfm?event=overview.process&ApplNo=761108\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761108
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:91845aeade1ac84b4119@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261020
DTEND;VALUE=DATE:20261021
SUMMARY:GLAXOSMITHKLINE APPROVAL: HIBSAGO
DESCRIPTION:Approved 2026-10-20: HIBSAGO (NDA221276 ORIG1)\nConfidence: con
 firmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?
 event=overview.process&ApplNo=221276\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=221276
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:47aba0979aece4d65475@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261019
DTEND;VALUE=DATE:20261020
SUMMARY:GLAXOSMITHKLINE APPROVAL: JEMPERLI
DESCRIPTION:Approved 2026-10-19: JEMPERLI (BLA761174 SUPPL15)\nConfidence: 
 confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.c
 fm?event=overview.process&ApplNo=761174\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761174
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:e9d87733028ed3ed5b85@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261019
DTEND;VALUE=DATE:20261020
SUMMARY:FRESENIUS MEDCL CARE APPROVAL: CIENBY
DESCRIPTION:Approved 2026-10-19: CIENBY (NDA219455 ORIG1)\nConfidence: conf
 irmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?e
 vent=overview.process&ApplNo=219455\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=219455
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:bfce8a142bed75c79dda@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261019
DTEND;VALUE=DATE:20261020
SUMMARY:FRESENIUS MEDCL CARE APPROVAL: CALREZDY
DESCRIPTION:Approved 2026-10-19: CALREZDY (NDA219456 ORIG1)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=219456\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=219456
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:cb41063c032ae150571f@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261016
DTEND;VALUE=DATE:20261017
SUMMARY:BLUEPRINT MEDICINES APPROVAL: AYVAKIT
DESCRIPTION:Approved 2026-10-16: AYVAKIT (NDA212608 SUPPL21)\nConfidence: c
 onfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cf
 m?event=overview.process&ApplNo=212608\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=212608
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:ab8247576bc73fc1fbeb@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261016
DTEND;VALUE=DATE:20261017
SUMMARY:FAMYGEN LIFE SCI APPROVAL: RYZUMVI
DESCRIPTION:Approved 2026-10-16: RYZUMVI (NDA217064 SUPPL5)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=217064\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=217064
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:7f12c8714adf06e86053@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261016
DTEND;VALUE=DATE:20261017
SUMMARY:ROSEMONT PHARMS APPROVAL: YULZETY
DESCRIPTION:Approved 2026-10-16: YULZETY (NDA221033 ORIG1)\nConfidence: con
 firmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?
 event=overview.process&ApplNo=221033\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=221033
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:514ca414165bf506bb10@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261016
DTEND;VALUE=DATE:20261017
SUMMARY:MRK APPROVAL: KEYTRUDA
DESCRIPTION:Approved 2026-10-16: KEYTRUDA (BLA125514 SUPPL191)\nConfidence:
  confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=125514
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:471a042ff4f3e9deb2d0@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261016
DTEND;VALUE=DATE:20261017
SUMMARY:MRK APPROVAL: KEYTRUDA QLEX
DESCRIPTION:Approved 2026-10-16: KEYTRUDA QLEX (BLA761467 SUPPL8)\nConfiden
 ce: confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata
 .fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761467\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761467
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:5ed3320c53ebd37ce83d@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261016
DTEND;VALUE=DATE:20261017
SUMMARY:ALC APPROVAL: BRYTLY
DESCRIPTION:Approved 2026-10-16: BRYTLY (NDA220341 ORIG1)\nConfidence: conf
 irmed\nTicker ALC (confidence 0.6)\nSource: https://www.accessdata.fda.gov
 /scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220341\nScheduli
 ng/reference data from public records\; dates can move. Not investment\, l
 egal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220341
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:13e5ba6cbb2460c6d345@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261015
DTEND;VALUE=DATE:20261016
SUMMARY:GENENTECH APPROVAL: ENSPRYNG
DESCRIPTION:Approved 2026-10-15: ENSPRYNG (BLA761149 SUPPL8)\nConfidence: c
 onfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cf
 m?event=overview.process&ApplNo=761149\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761149
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:3e87805a3a2875d73c03@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261015
DTEND;VALUE=DATE:20261016
SUMMARY:NVS APPROVAL: COSENTYX
DESCRIPTION:Approved 2026-10-15: COSENTYX (BLA761349 SUPPL13)\nConfidence: 
 confirmed\nTicker NVS (confidence 0.6)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761349\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761349
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:0cc81eb3c5378e793f83@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261015
DTEND;VALUE=DATE:20261016
SUMMARY:COSETTE APPROVAL: EVOXAC
DESCRIPTION:Approved 2026-10-15: EVOXAC (NDA221183 ORIG1)\nConfidence: conf
 irmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?e
 vent=overview.process&ApplNo=221183\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=221183
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:deba6619f706b2453321@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261015
DTEND;VALUE=DATE:20261016
SUMMARY:UCB INC APPROVAL: ZILBRYSQ
DESCRIPTION:Approved 2026-10-15: ZILBRYSQ (NDA216834 SUPPL15)\nConfidence: 
 confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.c
 fm?event=overview.process&ApplNo=216834\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=216834
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:63e7284a4c02dd3938da@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261014
DTEND;VALUE=DATE:20261015
SUMMARY:ALTOR BIOSCIENCE\, LLC\, AN INDIRECT WHOLLY-OWNED SU APPROVAL: ANKT
 IVA
DESCRIPTION:Approved 2026-10-14: ANKTIVA (BLA761336 SUPPL2)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=761336\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761336
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:d64c41c76b91f40802e7@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261014
DTEND;VALUE=DATE:20261015
SUMMARY:MRK APPROVAL: ENFLONSIA
DESCRIPTION:Approved 2026-10-14: ENFLONSIA (BLA761432 SUPPL3)\nConfidence: 
 confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761432\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761432
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:df1ae6794307ba0cbb4b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261013
DTEND;VALUE=DATE:20261014
SUMMARY:VIFOR FRESENIUS APPROVAL: VELPHORO
DESCRIPTION:Approved 2026-10-13: VELPHORO (NDA205109 SUPPL14)\nConfidence: 
 confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.c
 fm?event=overview.process&ApplNo=205109\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=205109
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:bcf17ad23c1a78e1eddb@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261009
DTEND;VALUE=DATE:20261010
SUMMARY:BRACCO APPROVAL: ISOVUE READI
DESCRIPTION:Approved 2026-10-09: ISOVUE READI (NDA220583 ORIG1)\nConfidence
 : confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index
 .cfm?event=overview.process&ApplNo=220583\nScheduling/reference data from 
 public records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220583
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:4864af6809795e377b84@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261009
DTEND;VALUE=DATE:20261010
SUMMARY:AICURIS ANTI-INFECT APPROVAL: HOVILPRI
DESCRIPTION:Approved 2026-10-09: HOVILPRI (NDA221154 ORIG1)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=221154\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=221154
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:c147175cd08f202d4adb@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261009
DTEND;VALUE=DATE:20261010
SUMMARY:LLY APPROVAL: OLUMIANT
DESCRIPTION:Approved 2026-10-09: OLUMIANT (NDA207924 SUPPL10)\nConfidence: 
 confirmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207924\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=207924
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:1e4415a12266799794fd@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261009
DTEND;VALUE=DATE:20261010
SUMMARY:AMGN APPROVAL: REPATHA
DESCRIPTION:Approved 2026-10-09: REPATHA (BLA125522 SUPPL47)\nConfidence: c
 onfirmed\nTicker AMGN (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125522\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=125522
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:690bed965c9c3747a624@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261008
DTEND;VALUE=DATE:20261009
SUMMARY:GENENTECH INC APPROVAL: TECENTRIQ HYBREZA
DESCRIPTION:Approved 2026-10-08: TECENTRIQ HYBREZA (BLA761347 SUPPL11)\nCon
 fidence: confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/da
 f/index.cfm?event=overview.process&ApplNo=761347\nScheduling/reference dat
 a from public records\; dates can move. Not investment\, legal or medical 
 advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761347
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:7e36da8b8a3aad7dd188@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261008
DTEND;VALUE=DATE:20261009
SUMMARY:GENENTECH INC APPROVAL: TECENTRIQ
DESCRIPTION:Approved 2026-10-08: TECENTRIQ (BLA761034 SUPPL65)\nConfidence:
  confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.
 cfm?event=overview.process&ApplNo=761034\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761034
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:b13995ddb65bc4973214@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261008
DTEND;VALUE=DATE:20261009
SUMMARY:TEVA APPROVAL: WELTRUZA
DESCRIPTION:Approved 2026-10-08: WELTRUZA (NDA219007 ORIG1)\nConfidence: co
 nfirmed\nTicker TEVA (confidence 0.6)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219007\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=219007
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:42c135cd435208ff20a7@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261008
DTEND;VALUE=DATE:20261009
SUMMARY:AZN APPROVAL: BREZTRI AEROSPHERE
DESCRIPTION:Approved 2026-10-08: BREZTRI AEROSPHERE (NDA220290 ORIG1)\nConf
 idence: confirmed\nTicker AZN (confidence 0.6)\nSource: https://www.access
 data.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=2202
 90\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220290
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:0288d18e1482220f28ba@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261007
DTEND;VALUE=DATE:20261008
SUMMARY:SEAGEN APPROVAL: TUKYSA
DESCRIPTION:Approved 2026-10-07: TUKYSA (NDA213411 SUPPL10)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=213411\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=213411
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:66f1a2c70cb2f4646965@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261006
DTEND;VALUE=DATE:20261007
SUMMARY:NVS APPROVAL: RHAPSIDO
DESCRIPTION:Approved 2026-10-06: RHAPSIDO (NDA218436 SUPPL1)\nConfidence: c
 onfirmed\nTicker NVS (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218436\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218436
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:0c90e926cf76d4a4ee17@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261002
DTEND;VALUE=DATE:20261003
SUMMARY:LOXO ONCOL APPROVAL: JAYPIRCA
DESCRIPTION:Approved 2026-10-02: JAYPIRCA (NDA216059 SUPPL6)\nConfidence: c
 onfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cf
 m?event=overview.process&ApplNo=216059\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=216059
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:bf5fa5c9f6a6b16b8806@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261001
DTEND;VALUE=DATE:20261002
SUMMARY:ADCOM (scheduled): AdCom 2026-10-01: Vaccines and Related Biologica
 l Products Advisory Committee
DESCRIPTION:AdCom 2026-10-01: Vaccines and Related Biological Products Advi
 sory Committee\nConfidence: scheduled\nSource: https://www.federalregister
 .gov/documents/2026/09/09/2026-18349/vaccines-and-related-biological-produ
 cts-advisory-committee-notice-of-meeting-establishment-of-a\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://www.federalregister.gov/documents/2026/09/09/2026-18349/vaccine
 s-and-related-biological-products-advisory-committee-notice-of-meeting-est
 ablishment-of-a
CATEGORIES:adcom,scheduled
END:VEVENT
BEGIN:VEVENT
UID:04b17f288dd53c168e9f@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261001
DTEND;VALUE=DATE:20261002
SUMMARY:EVER APPROVAL: TRABECTEDIN
DESCRIPTION:Approved 2026-10-01: TRABECTEDIN (NDA219617 ORIG1)\nConfidence:
  confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.
 cfm?event=overview.process&ApplNo=219617\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=219617
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:b92d1ef30d876c4e25f1@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260930
DTEND;VALUE=DATE:20261001
SUMMARY:BMY APPROVAL: CAMZYOS
DESCRIPTION:Approved 2026-09-30: CAMZYOS (NDA214998 SUPPL13)\nConfidence: c
 onfirmed\nTicker BMY (confidence 0.6)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214998\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=214998
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:99b4df7491c29e5c2383@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260930
DTEND;VALUE=DATE:20261001
SUMMARY:AGIO PDUFA (company-disclosed): PDUFA September 30\, 2026 - AGIOS P
 HARMACEUTICALS\, INC.
DESCRIPTION:PDUFA September 30\, 2026 - AGIOS PHARMACEUTICALS\, INC.\nConfi
 dence: company-disclosed\nTicker AGIO (confidence 1.0)\nSource: https://ww
 w.sec.gov/Archives/edgar/data/1439222/000143922226000129/agio-110526xfyxex
 991earnin.htm\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1439222/000143922226000129/agio
 -110526xfyxex991earnin.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:5fd858e40696007f7218@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260930
DTEND;VALUE=DATE:20261001
SUMMARY:SRRK PDUFA (company-disclosed): PDUFA September 30\, 2026 - Scholar
  Rock Holding Corp
DESCRIPTION:PDUFA September 30\, 2026 - Scholar Rock Holding Corp\nConfiden
 ce: company-disclosed\nTicker SRRK (confidence 1.0)\nSource: https://www.s
 ec.gov/Archives/edgar/data/1727196/000119312526336715/srrk-ex99_1.htm\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1727196/000119312526336715/srrk
 -ex99_1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:c0132c01d6548dd82e70@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260928
DTEND;VALUE=DATE:20260929
SUMMARY:RARE THYROID APPROVAL: EMCITATE
DESCRIPTION:Approved 2026-09-28: EMCITATE (NDA220963 ORIG1)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=220963\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220963
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:67a32cde24cd6d0a733f@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260925
DTEND;VALUE=DATE:20260926
SUMMARY:ABBV APPROVAL: JUVMO\; JUVMO (COPACKAGED)
DESCRIPTION:Approved 2026-09-25: JUVMO\; JUVMO (COPACKAGED) (NDA220415 ORIG
 1)\nConfidence: confirmed\nTicker ABBV (confidence 0.9)\nSource: https://w
 ww.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&Ap
 plNo=220415\nScheduling/reference data from public records\; dates can mov
 e. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220415
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:71c2ab1f4d1b2251e0f3@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260925
DTEND;VALUE=DATE:20260926
SUMMARY:ADVENTAPHARMA APPROVAL: ZUEINO
DESCRIPTION:Approved 2026-09-25: ZUEINO (NDA218379 ORIG1)\nConfidence: conf
 irmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?e
 vent=overview.process&ApplNo=218379\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218379
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:4542bb6ebf7dd5ea5746@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260925
DTEND;VALUE=DATE:20260926
SUMMARY:AZURITY APPROVAL: LAMLIQUE
DESCRIPTION:Approved 2026-09-25: LAMLIQUE (NDA221109 ORIG1)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=221109\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=221109
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:e6ec1ad92bd16007e09a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260925
DTEND;VALUE=DATE:20260926
SUMMARY:MIRM APPROVAL: ATEBRIOZ
DESCRIPTION:Approved 2026-09-25: ATEBRIOZ (NDA221198 ORIG1)\nConfidence: co
 nfirmed\nTicker MIRM (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=221198\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=221198
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:e2c2f7b0e994f751e804@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260925
DTEND;VALUE=DATE:20260926
SUMMARY:GENENTECH APPROVAL: GAZYVA
DESCRIPTION:Approved 2026-09-25: GAZYVA (BLA125486 SUPPL43)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=125486\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=125486
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:739b59e49142bb019ea0@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260925
DTEND;VALUE=DATE:20260926
SUMMARY:LLY APPROVAL: OLUMIANT
DESCRIPTION:Approved 2026-09-25: OLUMIANT (NDA207924 SUPPL9)\nConfidence: c
 onfirmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207924\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=207924
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:490fa36f6bb6d140b93b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260925
DTEND;VALUE=DATE:20260926
SUMMARY:TEVA APPROVAL: DEGEVMA
DESCRIPTION:Approved 2026-09-25: DEGEVMA (BLA761481 ORIG1)\nConfidence: con
 firmed\nTicker TEVA (confidence 0.6)\nSource: https://www.accessdata.fda.g
 ov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761481\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761481
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:da5a3f0117ac29122973@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260924
DTEND;VALUE=DATE:20260925
SUMMARY:EISAI INC APPROVAL: LENVIMA
DESCRIPTION:Approved 2026-09-24: LENVIMA (NDA206947 SUPPL35)\nConfidence: c
 onfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cf
 m?event=overview.process&ApplNo=206947\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=206947
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:427d9e08d1252f4cf6db@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260924
DTEND;VALUE=DATE:20260925
SUMMARY:MRK APPROVAL: WELIREG
DESCRIPTION:Approved 2026-09-24: WELIREG (NDA215383 SUPPL13)\nConfidence: c
 onfirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215383\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215383
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:87129a7138f7a0eb8d66@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260923
DTEND;VALUE=DATE:20260924
SUMMARY:ADCOM (scheduled): AdCom 2026-09-23: Molecular and Clinical Genetic
 s Panel of the Medical Devices Advisory Committee
DESCRIPTION:AdCom 2026-09-23: Molecular and Clinical Genetics Panel of the 
 Medical Devices Advisory Committee\nConfidence: scheduled\nSource: https:/
 /www.federalregister.gov/documents/2026/08/10/2026-16245/molecular-and-cli
 nical-genetics-panel-of-the-medical-devices-advisory-committee-notice-of-m
 eeting\nScheduling/reference data from public records\; dates can move. No
 t investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.federalregister.gov/documents/2026/08/10/2026-16245/molecul
 ar-and-clinical-genetics-panel-of-the-medical-devices-advisory-committee-n
 otice-of-meeting
CATEGORIES:adcom,scheduled
END:VEVENT
BEGIN:VEVENT
UID:804fb9fcc4ae307ec93f@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260923
DTEND;VALUE=DATE:20260924
SUMMARY:ELEVAR APPROVAL: LYRFIGTU
DESCRIPTION:Approved 2026-09-23: LYRFIGTU (NDA220425 ORIG1)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=220425\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220425
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:bb1487374e8fcfebfefb@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260923
DTEND;VALUE=DATE:20260924
SUMMARY:LLY APPROVAL: ONSWIK
DESCRIPTION:Approved 2026-09-23: ONSWIK (BLA761408 ORIG1)\nConfidence: conf
 irmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fda.go
 v/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761408\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761408
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:a2a54ec3a7358baea857@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260922
DTEND;VALUE=DATE:20260923
SUMMARY:AGL WELDING SUPPLY CO INC DBA AGL GAS TECHNOLOGIES APPROVAL: CARBON
  DIOXIDE\, USP
DESCRIPTION:Approved 2026-09-22: CARBON DIOXIDE\, USP (NDA222000 ORIG1)\nCo
 nfidence: confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/d
 af/index.cfm?event=overview.process&ApplNo=222000\nScheduling/reference da
 ta from public records\; dates can move. Not investment\, legal or medical
  advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=222000
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:dff45e0ec0fb6cdffbe2@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260921
DTEND;VALUE=DATE:20260922
SUMMARY:MRK APPROVAL: WINREVAIR
DESCRIPTION:Approved 2026-09-21: WINREVAIR (BLA761363 SUPPL12)\nConfidence:
  confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761363\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761363
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:58e5b4fc59974788153f@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260919
DTEND;VALUE=DATE:20260920
SUMMARY:RARE PDUFA (company-disclosed): apazunersen
DESCRIPTION:PDUFA September 19\, 2026 - Ultragenyx Pharmaceutical Inc. (apa
 zunersen)\nConfidence: company-disclosed\nTicker RARE (confidence 1.0)\nSo
 urce: https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/r
 are-ex99_1.htm\nScheduling/reference data from public records\; dates can 
 move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/rare
 -ex99_1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:c581653c32031d307ca4@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260918
DTEND;VALUE=DATE:20260919
SUMMARY:LLY APPROVAL: INLURIYO
DESCRIPTION:Approved 2026-09-18: INLURIYO (NDA218881 SUPPL1)\nConfidence: c
 onfirmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218881\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218881
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:d98d9ce817ba6626bfd7@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260918
DTEND;VALUE=DATE:20260919
SUMMARY:LLY APPROVAL: VERZENIO
DESCRIPTION:Approved 2026-09-18: VERZENIO (NDA208716 SUPPL22)\nConfidence: 
 confirmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=208716
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:d5aaf4eb8a74f589fbd4@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260918
DTEND;VALUE=DATE:20260919
SUMMARY:INTRABIO APPROVAL: AQNEURSA
DESCRIPTION:Approved 2026-09-18: AQNEURSA (NDA219132 SUPPL2)\nConfidence: c
 onfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cf
 m?event=overview.process&ApplNo=219132\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=219132
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:95b42190db8e5825f648@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260916
DTEND;VALUE=DATE:20260917
SUMMARY:ADCOM (scheduled): AdCom 2026-09-16: Pediatric Advisory Committee (
 PAC)
DESCRIPTION:AdCom 2026-09-16: Pediatric Advisory Committee (PAC)\nConfidenc
 e: scheduled\nSource: https://www.federalregister.gov/documents/2026/07/28
 /2026-15149/pediatric-advisory-committee-pac-notice-of-meeting-establishme
 nt-of-a-public-docket-request-for\nScheduling/reference data from public r
 ecords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.federalregister.gov/documents/2026/07/28/2026-15149/pediatr
 ic-advisory-committee-pac-notice-of-meeting-establishment-of-a-public-dock
 et-request-for
CATEGORIES:adcom,scheduled
END:VEVENT
BEGIN:VEVENT
UID:35aa0b45b06e68147be2@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260916
DTEND;VALUE=DATE:20260917
SUMMARY:NUVB APPROVAL: IBTROZI
DESCRIPTION:Approved 2026-09-16: IBTROZI (NDA219713 SUPPL4)\nConfidence: co
 nfirmed\nTicker NUVB (confidence 0.6)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219713\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=219713
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:a0d63d1f9b30c56b1553@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260916
DTEND;VALUE=DATE:20260917
SUMMARY:BAYER HLTHCARE APPROVAL: KERENDIA
DESCRIPTION:Approved 2026-09-16: KERENDIA (NDA215341 SUPPL11)\nConfidence: 
 confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.c
 fm?event=overview.process&ApplNo=215341\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215341
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:e16b0379fe964915d19a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260916
DTEND;VALUE=DATE:20260917
SUMMARY:AZN APPROVAL: TRUQAP
DESCRIPTION:Approved 2026-09-16: TRUQAP (NDA218197 SUPPL6)\nConfidence: con
 firmed\nTicker AZN (confidence 0.9)\nSource: https://www.accessdata.fda.go
 v/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218197
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:e4cc0376f4ff2aa9eec2@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260915
DTEND;VALUE=DATE:20260916
SUMMARY:EMERGE BIOSCIENCE PTE. LTD. APPROVAL: GARZULYS
DESCRIPTION:Approved 2026-09-15: GARZULYS (BLA761497 ORIG2)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=761497\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761497
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:2b8764162a0ac6974784@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260914
DTEND;VALUE=DATE:20260915
SUMMARY:AZN APPROVAL: TAGRISSO
DESCRIPTION:Approved 2026-09-14: TAGRISSO (NDA208065 SUPPL35)\nConfidence: 
 confirmed\nTicker AZN (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=208065
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:12994640616f233dab59@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260914
DTEND;VALUE=DATE:20260915
SUMMARY:CURIUM APPROVAL: BEXLUTRY
DESCRIPTION:Approved 2026-09-14: BEXLUTRY (NDA218525 ORIG1)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=218525\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218525
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:ca3dfa0ef9413f0fa367@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260911
DTEND;VALUE=DATE:20260912
SUMMARY:SRRK APPROVAL: ISEMBYLD
DESCRIPTION:Approved 2026-09-11: ISEMBYLD (BLA761463 ORIG1)\nConfidence: co
 nfirmed\nTicker SRRK (confidence 0.6)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761463\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761463
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:8e1be2cc67174cd697bb@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260911
DTEND;VALUE=DATE:20260912
SUMMARY:TLX APPROVAL: PIXCLARA
DESCRIPTION:Approved 2026-09-11: PIXCLARA (NDA218592 ORIG1)\nConfidence: co
 nfirmed\nTicker TLX (confidence 0.9)\nSource: https://www.accessdata.fda.g
 ov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218592\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218592
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:904820ef2f4c805b9518@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260911
DTEND;VALUE=DATE:20260912
SUMMARY:PHAR APPROVAL: JOENJA
DESCRIPTION:Approved 2026-09-11: JOENJA (NDA217759 SUPPL6)\nConfidence: con
 firmed\nTicker PHAR (confidence 0.9)\nSource: https://www.accessdata.fda.g
 ov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217759\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=217759
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:9a4fe0cbd7eb140ca136@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260909
DTEND;VALUE=DATE:20260910
SUMMARY:SEIKAGAKU Corporation CRL: SI-6603 (condoliase) injection
DESCRIPTION:CRL 2026-09-09: SEIKAGAKU Corporation BLA 761393 (SI-6603 (cond
 oliase) injection)\nConfidence: confirmed\nSource: https://download.open.f
 da.gov/crl/CRL_BLA761393_20260909.pdf\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_BLA761393_20260909.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:fa75410199d8b352d72b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260909
DTEND;VALUE=DATE:20260910
SUMMARY:BFRI APPROVAL: AMELUZ
DESCRIPTION:Approved 2026-09-09: AMELUZ (NDA208081 SUPPL40)\nConfidence: co
 nfirmed\nTicker BFRI (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208081\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=208081
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:426d05388c15510a5383@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260909
DTEND;VALUE=DATE:20260910
SUMMARY:BAYER HEALTHCARE APPROVAL: HYRNUO
DESCRIPTION:Approved 2026-09-09: HYRNUO (NDA219972 SUPPL1)\nConfidence: con
 firmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?
 event=overview.process&ApplNo=219972\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=219972
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:03b7fa12f94865389b12@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260904
DTEND;VALUE=DATE:20260905
SUMMARY:AZN APPROVAL: ETCAMAH
DESCRIPTION:Approved 2026-09-04: ETCAMAH (NDA220359 ORIG1)\nConfidence: con
 firmed\nTicker AZN (confidence 0.9)\nSource: https://www.accessdata.fda.go
 v/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220359\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220359
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:bc5789d5f00da43f63a0@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260903
DTEND;VALUE=DATE:20260904
SUMMARY:HANDA ONCOL APPROVAL: OMCAZIO
DESCRIPTION:Approved 2026-09-03: OMCAZIO (NDA220613 ORIG1)\nConfidence: con
 firmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?
 event=overview.process&ApplNo=220613\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220613
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:e09a255ea3f41fd085b2@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260903
DTEND;VALUE=DATE:20260904
SUMMARY:IONS APPROVAL: ZANVASTRO
DESCRIPTION:Approved 2026-09-03: ZANVASTRO (NDA220210 ORIG1)\nConfidence: c
 onfirmed\nTicker IONS (confidence 0.6)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220210\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220210
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:b721f9838116fe554ee3@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260828
DTEND;VALUE=DATE:20260829
SUMMARY:PHARMAESSENTIA CORP APPROVAL: BESREMI
DESCRIPTION:Approved 2026-08-28: BESREMI (BLA761166 SUPPL13)\nConfidence: c
 onfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cf
 m?event=overview.process&ApplNo=761166\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761166
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:d231270d89944eaf7f57@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260828
DTEND;VALUE=DATE:20260829
SUMMARY:TAK APPROVAL: MIMRYLO
DESCRIPTION:Approved 2026-08-28: MIMRYLO (NDA220605 ORIG1)\nConfidence: con
 firmed\nTicker TAK (confidence 0.6)\nSource: https://www.accessdata.fda.go
 v/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220605\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220605
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:ca1fc31d4f1c927b3bcf@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260828
DTEND;VALUE=DATE:20260829
SUMMARY:JANSSEN BIOTECH APPROVAL: STELARA
DESCRIPTION:Approved 2026-08-28: STELARA (BLA761044 SUPPL21)\nConfidence: c
 onfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cf
 m?event=overview.process&ApplNo=761044\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761044
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:4ec366c86390448eb853@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260827
DTEND;VALUE=DATE:20260828
SUMMARY:LLY APPROVAL: MOUNJARO\; MOUNJARO (AUTOINJECTOR)\; MOUNJARO KWIKPEN
DESCRIPTION:Approved 2026-08-27: MOUNJARO\; MOUNJARO (AUTOINJECTOR)\; MOUNJ
 ARO KWIKPEN (NDA215866 SUPPL44)\nConfidence: confirmed\nTicker LLY (confid
 ence 0.95)\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.
 cfm?event=overview.process&ApplNo=215866\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215866
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:05829244ae34ed1cb49d@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260827
DTEND;VALUE=DATE:20260828
SUMMARY:LLY APPROVAL: MOUNJARO\; MOUNJARO (AUTOINJECTOR)\; MOUNJARO KWIKPEN
DESCRIPTION:Approved 2026-08-27: MOUNJARO\; MOUNJARO (AUTOINJECTOR)\; MOUNJ
 ARO KWIKPEN (NDA215866 SUPPL45)\nConfidence: confirmed\nTicker LLY (confid
 ence 0.95)\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.
 cfm?event=overview.process&ApplNo=215866\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215866
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:367d8b0a437877c77703@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260827
DTEND;VALUE=DATE:20260828
SUMMARY:GILD APPROVAL: BIXLENVO
DESCRIPTION:Approved 2026-08-27: BIXLENVO (NDA221104 ORIG1)\nConfidence: co
 nfirmed\nTicker GILD (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=221104\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=221104
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:14370f43179cb92a78d6@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260827
DTEND;VALUE=DATE:20260828
SUMMARY:GILD APPROVAL: BIXLENVO SUNLENCA STARTER PACK (COPACKAGED)
DESCRIPTION:Approved 2026-08-27: BIXLENVO SUNLENCA STARTER PACK (COPACKAGED
 ) (NDA221443 ORIG1)\nConfidence: confirmed\nTicker GILD (confidence 0.9)\n
 Source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=ov
 erview.process&ApplNo=221443\nScheduling/reference data from public record
 s\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=221443
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:ee3083ae65a1c90becf5@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260827
DTEND;VALUE=DATE:20260828
SUMMARY:GILD APPROVAL: SUNLENCA
DESCRIPTION:Approved 2026-08-27: SUNLENCA (NDA215973 SUPPL24)\nConfidence: 
 confirmed\nTicker GILD (confidence 0.9)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215973\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215973
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:bdc44aaece0fc0fe64cb@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260827
DTEND;VALUE=DATE:20260828
SUMMARY:GILD APPROVAL: SUNLENCA
DESCRIPTION:Approved 2026-08-27: SUNLENCA (NDA215974 SUPPL17)\nConfidence: 
 confirmed\nTicker GILD (confidence 0.9)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215974\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215974
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:7a18fa42eb643ddd2bd0@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260827
DTEND;VALUE=DATE:20260828
SUMMARY:PRIOVANT THERAP APPROVAL: LISRAYA
DESCRIPTION:Approved 2026-08-27: LISRAYA (NDA220106 ORIG1)\nConfidence: con
 firmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?
 event=overview.process&ApplNo=220106\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220106
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:a2148587b73bddee06dc@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260826
DTEND;VALUE=DATE:20260827
SUMMARY:LLY APPROVAL: ZEPBOUND\; ZEPBOUND (AUTOINJECTOR)\; ZEPBOUND KWIKPEN
DESCRIPTION:Approved 2026-08-26: ZEPBOUND\; ZEPBOUND (AUTOINJECTOR)\; ZEPBO
 UND KWIKPEN (NDA217806 SUPPL41)\nConfidence: confirmed\nTicker LLY (confid
 ence 0.95)\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.
 cfm?event=overview.process&ApplNo=217806\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=217806
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:0d79267228d03855dda1@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260826
DTEND;VALUE=DATE:20260827
SUMMARY:RVMD APPROVAL: RASONQUE
DESCRIPTION:Approved 2026-08-26: RASONQUE (NDA220910 ORIG1)\nConfidence: co
 nfirmed\nTicker RVMD (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220910\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220910
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:e509a3ac7332eac44281@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260826
DTEND;VALUE=DATE:20260827
SUMMARY:SUN PHARM APPROVAL: VOBRIG
DESCRIPTION:Approved 2026-08-26: VOBRIG (NDA213225 ORIG1)\nConfidence: conf
 irmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?e
 vent=overview.process&ApplNo=213225\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=213225
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:2513161dd77753f74cfb@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260825
DTEND;VALUE=DATE:20260826
SUMMARY:BEIGENE APPROVAL: TEVIMBRA
DESCRIPTION:Approved 2026-08-25: TEVIMBRA (BLA761232 SUPPL18)\nConfidence: 
 confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.c
 fm?event=overview.process&ApplNo=761232\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761232
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:169ce390474878581a9c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260825
DTEND;VALUE=DATE:20260826
SUMMARY:JAZZ APPROVAL: ZIIHERA
DESCRIPTION:Approved 2026-08-25: ZIIHERA (BLA761416 SUPPL2)\nConfidence: co
 nfirmed\nTicker JAZZ (confidence 0.6)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761416\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761416
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:69f49e0914e45a674582@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260825
DTEND;VALUE=DATE:20260826
SUMMARY:VIIV HLTHCARE APPROVAL: TIVICAY
DESCRIPTION:Approved 2026-08-25: TIVICAY (NDA204790 SUPPL34)\nConfidence: c
 onfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cf
 m?event=overview.process&ApplNo=204790\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=204790
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:0012c9144c69e17f6ec9@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260825
DTEND;VALUE=DATE:20260826
SUMMARY:VIIV HLTHCARE APPROVAL: TIVICAY PD
DESCRIPTION:Approved 2026-08-25: TIVICAY PD (NDA213983 SUPPL7)\nConfidence:
  confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.
 cfm?event=overview.process&ApplNo=213983\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=213983
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:105a731924667dfff113@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260825
DTEND;VALUE=DATE:20260826
SUMMARY:ZYME PDUFA (company-disclosed): zanidatamab
DESCRIPTION:PDUFA August 25\, 2026 - Zymeworks Inc. (zanidatamab)\nConfiden
 ce: company-disclosed\nTicker ZYME (confidence 1.0)\nSource: https://www.s
 ec.gov/Archives/edgar/data/1937653/000193765326000046/ex991q22026_earnings
 xrelea.htm\nScheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1937653/000193765326000046/ex99
 1q22026_earningsxrelea.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:e14b9014f756ee7dcd65@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260824
DTEND;VALUE=DATE:20260825
SUMMARY:JANSSEN BIOTECH APPROVAL: IMAAVY
DESCRIPTION:Approved 2026-08-24: IMAAVY (BLA761430 SUPPL2)\nConfidence: con
 firmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?
 event=overview.process&ApplNo=761430\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761430
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:d1710f32f22254e4b237@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260823
DTEND;VALUE=DATE:20260824
SUMMARY:RARE PDUFA (company-disclosed): rebisufligene
DESCRIPTION:PDUFA August 23\, 2026 - Ultragenyx Pharmaceutical Inc. (rebisu
 fligene)\nConfidence: company-disclosed\nTicker RARE (confidence 1.0)\nSou
 rce: https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/ra
 re-ex99_1.htm\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/rare
 -ex99_1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:468a63f63aa3bcd4cce5@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260820
DTEND;VALUE=DATE:20260821
SUMMARY:APELLIS PHARMS APPROVAL: EMPAVELI
DESCRIPTION:Approved 2026-08-20: EMPAVELI (NDA215014 SUPPL12)\nConfidence: 
 confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.c
 fm?event=overview.process&ApplNo=215014\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215014
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:9fce70662728520f072c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260819
DTEND;VALUE=DATE:20260820
SUMMARY:REGN APPROVAL: PASATRU
DESCRIPTION:Approved 2026-08-19: PASATRU (BLA761508 ORIG1)\nConfidence: con
 firmed\nTicker REGN (confidence 0.9)\nSource: https://www.accessdata.fda.g
 ov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761508\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761508
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:e51510cd676986217e39@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260818
DTEND;VALUE=DATE:20260819
SUMMARY:SamChunDang Pharm. Co.\, Ltd. CRL: SCD411
DESCRIPTION:CRL 2026-08-18: SamChunDang Pharm. Co.\, Ltd. BLA 761494 (SCD41
 1)\nConfidence: confirmed\nSource: https://download.open.fda.gov/crl/CRL_B
 LA761494_20260818.pdf\nScheduling/reference data from public records\; dat
 es can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_BLA761494_20260818.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:7564548d85440696a563@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260818
DTEND;VALUE=DATE:20260819
SUMMARY:Xspray Pharma AB CRL: CRL 2026-08-18: Xspray Pharma AB NDA 216195
DESCRIPTION:CRL 2026-08-18: Xspray Pharma AB NDA 216195\nConfidence: confir
 med\nSource: https://download.open.fda.gov/crl/CRL_NDA216195_20260818.pdf\
 nScheduling/reference data from public records\; dates can move. Not inves
 tment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_NDA216195_20260818.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:6f9e95b2698c2d7457fd@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260814
DTEND;VALUE=DATE:20260815
SUMMARY:BIOCON BIOLOGICS INC APPROVAL: YESINTEK
DESCRIPTION:Approved 2026-08-14: YESINTEK (BLA761406 SUPPL2)\nConfidence: c
 onfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cf
 m?event=overview.process&ApplNo=761406\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761406
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:20e9f9333b5fad2f7f2e@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260814
DTEND;VALUE=DATE:20260815
SUMMARY:BAX APPROVAL: SODIUM BICARBONATE
DESCRIPTION:Approved 2026-08-14: SODIUM BICARBONATE (NDA218524 ORIG1)\nConf
 idence: confirmed\nTicker BAX (confidence 0.6)\nSource: https://www.access
 data.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=2185
 24\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218524
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:b3223e5419e418e31b78@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260813
DTEND;VALUE=DATE:20260814
SUMMARY:CERVEAU LANTHEUS APPROVAL: TAUKLARIFY
DESCRIPTION:Approved 2026-08-13: TAUKLARIFY (NDA220496 ORIG1)\nConfidence: 
 confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.c
 fm?event=overview.process&ApplNo=220496\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220496
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:8dd69212e162aac7a9a6@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260813
DTEND;VALUE=DATE:20260814
SUMMARY:BMY APPROVAL: ZENBEXUS
DESCRIPTION:Approved 2026-08-13: ZENBEXUS (NDA221075 ORIG1)\nConfidence: co
 nfirmed\nTicker BMY (confidence 0.9)\nSource: https://www.accessdata.fda.g
 ov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=221075\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=221075
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:cbdcf893d3701241a401@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260809
DTEND;VALUE=DATE:20260810
SUMMARY:LIN APPROVAL: NITROUS OXIDE\, USP
DESCRIPTION:Approved 2026-08-09: NITROUS OXIDE\, USP (NDA221892 ORIG1)\nCon
 fidence: confirmed\nTicker LIN (confidence 0.6)\nSource: https://www.acces
 sdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=221
 892\nScheduling/reference data from public records\; dates can move. Not i
 nvestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=221892
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:513ce3f4fe16abd81ca7@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260807
DTEND;VALUE=DATE:20260808
SUMMARY:ITM Solucin GmbH CRL: MPA (Iutetium Lu177 edotreotide) injection
DESCRIPTION:CRL 2026-08-07: ITM Solucin GmbH NDA 218705 (MPA (Iutetium Lu17
 7 edotreotide) injection)\nConfidence: confirmed\nSource: https://download
 .open.fda.gov/crl/CRL_NDA218705_20260807.pdf\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_NDA218705_20260807.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:1a55b1c8a3bad1fb3e36@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260805
DTEND;VALUE=DATE:20260806
SUMMARY:TAK APPROVAL: ORZEYFUL
DESCRIPTION:Approved 2026-08-05: ORZEYFUL (NDA220860 ORIG1)\nConfidence: co
 nfirmed\nTicker TAK (confidence 0.6)\nSource: https://www.accessdata.fda.g
 ov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220860\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220860
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:50215e8906b4e45a81bb@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260805
DTEND;VALUE=DATE:20260806
SUMMARY:MRNA PDUFA (company-disclosed): PDUFA August 5 - Moderna\, Inc.
DESCRIPTION:PDUFA August 5 - Moderna\, Inc.\nConfidence: company-disclosed\
 nTicker MRNA (confidence 1.0)\nSource: https://www.sec.gov/Archives/edgar/
 data/1682852/000168285226000147/exhibit9912026q2pressrelea.htm\nScheduling
 /reference data from public records\; dates can move. Not investment\, leg
 al or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/exhi
 bit9912026q2pressrelea.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:3ae8ed265960024bbafe@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260731
DTEND;VALUE=DATE:20260801
SUMMARY:NVS APPROVAL: PLUVICTO
DESCRIPTION:Approved 2026-07-31: PLUVICTO (NDA215833 SUPPL37)\nConfidence: 
 confirmed\nTicker NVS (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215833\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215833
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:36b29d719c97e74d5811@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260731
DTEND;VALUE=DATE:20260801
SUMMARY:DR REDDYS LABS SA APPROVAL: ZIMRIXBY
DESCRIPTION:Approved 2026-07-31: ZIMRIXBY (BLA761376 ORIG1)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=761376\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761376
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:bf8bb50d21a47dc23724@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260730
DTEND;VALUE=DATE:20260731
SUMMARY:REPL ADCOM (scheduled): AdCom 2026-07-30: Cellular\, Tissue\, and G
 ene Therapies Advisory Committee - BLA 125827
DESCRIPTION:AdCom 2026-07-30: Cellular\, Tissue\, and Gene Therapies Adviso
 ry Committee - BLA 125827\nConfidence: scheduled\nTicker REPL (confidence 
 0.9)\nSource: https://www.federalregister.gov/documents/2026/07/08/2026-13
 810/cellular-tissue-and-gene-therapies-advisory-committee-notice-of-meetin
 g-establishment-of-a-public\nScheduling/reference data from public records
 \; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.federalregister.gov/documents/2026/07/08/2026-13810/cellula
 r-tissue-and-gene-therapies-advisory-committee-notice-of-meeting-establish
 ment-of-a-public
CATEGORIES:adcom,scheduled
END:VEVENT
BEGIN:VEVENT
UID:0671d1eca5361d55fba0@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260730
DTEND;VALUE=DATE:20260731
SUMMARY:REPL ADCOM (scheduled): AdCom 2026-07-30: Cellular\, Tissue\, and G
 ene Therapies Advisory Committee - BLA 125827
DESCRIPTION:AdCom 2026-07-30: Cellular\, Tissue\, and Gene Therapies Adviso
 ry Committee - BLA 125827\nConfidence: scheduled\nTicker REPL (confidence 
 0.9)\nSource: https://www.federalregister.gov/documents/2026/07/24/2026-15
 017/cellular-tissue-and-gene-therapies-advisory-committee-notice-of-meetin
 g-establishment-of-a-public\nScheduling/reference data from public records
 \; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.federalregister.gov/documents/2026/07/24/2026-15017/cellula
 r-tissue-and-gene-therapies-advisory-committee-notice-of-meeting-establish
 ment-of-a-public
CATEGORIES:adcom,scheduled
END:VEVENT
BEGIN:VEVENT
UID:337da3311e1e9801e8a7@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260729
DTEND;VALUE=DATE:20260730
SUMMARY:CAPR ADCOM (scheduled): AdCom 2026-07-29: Cellular\, Tissue\, and G
 ene Therapies Advisory Committee - BLA 125842
DESCRIPTION:AdCom 2026-07-29: Cellular\, Tissue\, and Gene Therapies Adviso
 ry Committee - BLA 125842\nConfidence: scheduled\nTicker CAPR (confidence 
 0.9)\nSource: https://www.federalregister.gov/documents/2026/06/29/2026-13
 096/cellular-tissue-and-gene-therapies-advisory-committee-notice-of-meetin
 g-establishment-of-a-public\nScheduling/reference data from public records
 \; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.federalregister.gov/documents/2026/06/29/2026-13096/cellula
 r-tissue-and-gene-therapies-advisory-committee-notice-of-meeting-establish
 ment-of-a-public
CATEGORIES:adcom,scheduled
END:VEVENT
BEGIN:VEVENT
UID:2f95b7969fbdb250cc66@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260729
DTEND;VALUE=DATE:20260730
SUMMARY:CAPR ADCOM (scheduled): AdCom 2026-07-29: Cellular\, Tissue\, and G
 ene Therapies Advisory Committee - BLA 125842
DESCRIPTION:AdCom 2026-07-29: Cellular\, Tissue\, and Gene Therapies Adviso
 ry Committee - BLA 125842\nConfidence: scheduled\nTicker CAPR (confidence 
 0.9)\nSource: https://www.federalregister.gov/documents/2026/07/24/2026-15
 016/cellular-tissue-and-gene-therapies-advisory-committee-amendment-of-not
 ice-biologics-license\nScheduling/reference data from public records\; dat
 es can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.federalregister.gov/documents/2026/07/24/2026-15016/cellula
 r-tissue-and-gene-therapies-advisory-committee-amendment-of-notice-biologi
 cs-license
CATEGORIES:adcom,scheduled
END:VEVENT
BEGIN:VEVENT
UID:18e32b81392f6cdc282b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260729
DTEND;VALUE=DATE:20260730
SUMMARY:Fresenius Kabi USA\, LLC CRL: Glycophos (sodium glycerophosphate in
 jection)
DESCRIPTION:CRL 2026-07-29: Fresenius Kabi USA\, LLC NDA 220381/Original 2\
 , NDA 220381 (Glycophos (sodium glycerophosphate injection))\nConfidence: 
 confirmed\nSource: https://download.open.fda.gov/crl/CRL_NDA220381_2026072
 9.pdf\nScheduling/reference data from public records\; dates can move. Not
  investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_NDA220381_20260729.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:50704c6647a2276d206d@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260729
DTEND;VALUE=DATE:20260730
SUMMARY:FRESENIUS KABI USA APPROVAL: GLYCOPHOS
DESCRIPTION:Approved 2026-07-29: GLYCOPHOS (NDA220381 ORIG1)\nConfidence: c
 onfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cf
 m?event=overview.process&ApplNo=220381\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220381
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:9715c2e0f0f08ed2713f@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260729
DTEND;VALUE=DATE:20260730
SUMMARY:CMP DEV LLC APPROVAL: QLONILIK
DESCRIPTION:Approved 2026-07-29: QLONILIK (NDA221094 ORIG1)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=221094\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=221094
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:bb71359a8886e2d1a377@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260729
DTEND;VALUE=DATE:20260730
SUMMARY:OTLK PDUFA (company-disclosed): bevacizumab-vikg
DESCRIPTION:PDUFA July 29\, 2026 - Outlook Therapeutics\, Inc. (bevacizumab
 -vikg)\nConfidence: company-disclosed\nTicker OTLK (confidence 1.0)\nSourc
 e: https://www.sec.gov/Archives/edgar/data/1649989/000110465926074346/tm26
 18010d1_ex99-1.htm\nScheduling/reference data from public records\; dates 
 can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1649989/000110465926074346/tm26
 18010d1_ex99-1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:8db5b91c7c809d3ad167@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260728
DTEND;VALUE=DATE:20260729
SUMMARY:VTRS APPROVAL: GWYN LO
DESCRIPTION:Approved 2026-07-28: GWYN LO (NDA219990 ORIG1)\nConfidence: con
 firmed\nTicker VTRS (confidence 0.6)\nSource: https://www.accessdata.fda.g
 ov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219990\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=219990
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:defba55ea5b4029df2b2@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260724
DTEND;VALUE=DATE:20260725
SUMMARY:ASTELLAS APPROVAL: XTANDI
DESCRIPTION:Approved 2026-07-24: XTANDI (NDA213674 SUPPL16)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=213674\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=213674
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:1e98829dd57ee1aa0ce9@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260724
DTEND;VALUE=DATE:20260725
SUMMARY:OTLK APPROVAL: LYTENAVA
DESCRIPTION:Approved 2026-07-24: LYTENAVA (BLA761320 ORIG1)\nConfidence: co
 nfirmed\nTicker OTLK (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761320\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761320
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:9523de52bab19a92890d@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260724
DTEND;VALUE=DATE:20260725
SUMMARY:KENVUE BRANDS APPROVAL: TYLENOL WITH NAPROXEN
DESCRIPTION:Approved 2026-07-24: TYLENOL WITH NAPROXEN (NDA219962 ORIG1)\nC
 onfidence: confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/
 daf/index.cfm?event=overview.process&ApplNo=219962\nScheduling/reference d
 ata from public records\; dates can move. Not investment\, legal or medica
 l advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=219962
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:355c515b979e538fda2a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260724
DTEND;VALUE=DATE:20260725
SUMMARY:MRBK APPROVAL: IDKIT:HP
DESCRIPTION:Approved 2026-07-24: IDKIT:HP (NDA021314 SUPPL14)\nConfidence: 
 confirmed\nTicker MRBK (confidence 0.9)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021314\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=021314
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:101482b9832db689272e@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260724
DTEND;VALUE=DATE:20260725
SUMMARY:EMERGE BIOSCIENCE PTE. LTD. APPROVAL: GARZULYS
DESCRIPTION:Approved 2026-07-24: GARZULYS (BLA761497 ORIG1)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=761497\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761497
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:9cd8b925e4d8e6f2e81e@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260724
DTEND;VALUE=DATE:20260725
SUMMARY:OTSUKA APPROVAL: SIMTRIYO
DESCRIPTION:Approved 2026-07-24: SIMTRIYO (NDA218145 ORIG1)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=218145\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218145
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:d21bc4b7c334d207d50a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260724
DTEND;VALUE=DATE:20260725
SUMMARY:ASTELLAS APPROVAL: XTANDI
DESCRIPTION:Approved 2026-07-24: XTANDI (NDA203415 SUPPL26)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=203415\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=203415
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:5b80289195bc7f26d069@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260723
DTEND;VALUE=DATE:20260724
SUMMARY:ADCOM (scheduled): AdCom 2026-07-23: Pharmacy Compounding Advisory 
 Committee
DESCRIPTION:AdCom 2026-07-23: Pharmacy Compounding Advisory Committee\nConf
 idence: scheduled\nSource: https://www.federalregister.gov/documents/2026/
 04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting
 -establishment-of-a-public-docket-request\nScheduling/reference data from 
 public records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmac
 y-compounding-advisory-committee-notice-of-meeting-establishment-of-a-publ
 ic-docket-request
CATEGORIES:adcom,scheduled
END:VEVENT
BEGIN:VEVENT
UID:c10ea477edc4db8d0ba8@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260723
DTEND;VALUE=DATE:20260724
SUMMARY:SCPHARMACEUTICALS APPROVAL: FUROSCIX\; FUROSCIX READYFLOW (AUTOINJE
 CTOR)
DESCRIPTION:Approved 2026-07-23: FUROSCIX\; FUROSCIX READYFLOW (AUTOINJECTO
 R) (NDA209988 SUPPL7)\nConfidence: confirmed\nSource: https://www.accessda
 ta.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209988
 \nScheduling/reference data from public records\; dates can move. Not inve
 stment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=209988
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:9295b90a0b9d27551920@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260723
DTEND;VALUE=DATE:20260724
SUMMARY:AETERNA ZENTARIS APPROVAL: MACRILEN
DESCRIPTION:Approved 2026-07-23: MACRILEN (NDA205598 SUPPL5)\nConfidence: c
 onfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cf
 m?event=overview.process&ApplNo=205598\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=205598
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:8fe8d01d45785c9adde4@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260722
DTEND;VALUE=DATE:20260723
SUMMARY:NUVALENT APPROVAL: JIDEYTRO
DESCRIPTION:Approved 2026-07-22: JIDEYTRO (NDA220185 ORIG1)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=220185\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220185
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:8bf715ebab35e98d77e9@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260721
DTEND;VALUE=DATE:20260722
SUMMARY:Apiject Systems Corp. CRL: glycopyrrolate solution
DESCRIPTION:CRL 2026-07-21: Apiject Systems Corp. NDA 219107 (glycopyrrolat
 e solution)\nConfidence: confirmed\nSource: https://download.open.fda.gov/
 crl/CRL_NDA219107_20260721.pdf\nScheduling/reference data from public reco
 rds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_NDA219107_20260721.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:a22ff915e9153ac317c1@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260719
DTEND;VALUE=DATE:20260720
SUMMARY:NE APPROVAL: AIR
DESCRIPTION:Approved 2026-07-19: AIR (NDA221805 ORIG1)\nConfidence: confirm
 ed\nTicker NE (confidence 0.6)\nSource: https://www.accessdata.fda.gov/scr
 ipts/cder/daf/index.cfm?event=overview.process&ApplNo=221805\nScheduling/r
 eference data from public records\; dates can move. Not investment\, legal
  or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=221805
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:0088986c5a4a27340088@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260716
DTEND;VALUE=DATE:20260717
SUMMARY:MUNDIPHARMA APPROVAL: REZZAYO
DESCRIPTION:Approved 2026-07-16: REZZAYO (NDA217417 SUPPL7)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=217417\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=217417
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:2167a59f8251e5bfb139@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260716
DTEND;VALUE=DATE:20260717
SUMMARY:NVS APPROVAL: FABHALTA
DESCRIPTION:Approved 2026-07-16: FABHALTA (NDA218276 SUPPL7)\nConfidence: c
 onfirmed\nTicker NVS (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218276\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218276
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:4d5fbc0d2466f65bf718@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260716
DTEND;VALUE=DATE:20260717
SUMMARY:SUN PHARMA GLOBAL APPROVAL: ILUMYA
DESCRIPTION:Approved 2026-07-16: ILUMYA (BLA761067 SUPPL27)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=761067\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761067
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:e6bca29f0315fda39764@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260715
DTEND;VALUE=DATE:20260716
SUMMARY:MSD APPROVAL: LIPFENDRA
DESCRIPTION:Approved 2026-07-15: LIPFENDRA (NDA220848 ORIG1)\nConfidence: c
 onfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cf
 m?event=overview.process&ApplNo=220848\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220848
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:0a758e53560297ebd94a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260714
DTEND;VALUE=DATE:20260715
SUMMARY:CELC APPROVAL: REVTORPYK
DESCRIPTION:Approved 2026-07-14: REVTORPYK (NDA219908 ORIG1)\nConfidence: c
 onfirmed\nTicker CELC (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219908\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=219908
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:110dd4ba68988b18313c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260714
DTEND;VALUE=DATE:20260715
SUMMARY:LLY APPROVAL: RETEVMO
DESCRIPTION:Approved 2026-07-14: RETEVMO (NDA218160 SUPPL7)\nConfidence: co
 nfirmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218160\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218160
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:814fe8c1f7af164c4fc0@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260714
DTEND;VALUE=DATE:20260715
SUMMARY:LLY APPROVAL: RETEVMO
DESCRIPTION:Approved 2026-07-14: RETEVMO (NDA213246 SUPPL17)\nConfidence: c
 onfirmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213246\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=213246
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:ceae3c00c3667a909bdd@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260713
DTEND;VALUE=DATE:20260714
SUMMARY:EISAI INC APPROVAL: LEQEMBI IQLIK
DESCRIPTION:Approved 2026-07-13: LEQEMBI IQLIK (BLA761375 SUPPL1)\nConfiden
 ce: confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/ind
 ex.cfm?event=overview.process&ApplNo=761375\nScheduling/reference data fro
 m public records\; dates can move. Not investment\, legal or medical advic
 e.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761375
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:2711c4146151465cb7ee@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260713
DTEND;VALUE=DATE:20260714
SUMMARY:LLY APPROVAL: VERZENIO
DESCRIPTION:Approved 2026-07-13: VERZENIO (NDA208716 SUPPL21)\nConfidence: 
 confirmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=208716
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:94b359b26e148ba1261b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260710
DTEND;VALUE=DATE:20260711
SUMMARY:MRK APPROVAL: KEYTRUDA
DESCRIPTION:Approved 2026-07-10: KEYTRUDA (BLA125514 SUPPL194)\nConfidence:
  confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=125514
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:64f8cddced87634dca26@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260710
DTEND;VALUE=DATE:20260711
SUMMARY:MRK APPROVAL: KEYTRUDA QLEX
DESCRIPTION:Approved 2026-07-10: KEYTRUDA QLEX (BLA761467 SUPPL12)\nConfide
 nce: confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdat
 a.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761467\
 nScheduling/reference data from public records\; dates can move. Not inves
 tment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761467
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:6f6f94e5322ab294e037@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260710
DTEND;VALUE=DATE:20260711
SUMMARY:PROVEPHARM SAS APPROVAL: ZYOGREEN
DESCRIPTION:Approved 2026-07-10: ZYOGREEN (NDA218579 ORIG1)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=218579\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218579
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:6ec4f9118bbec363028b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260710
DTEND;VALUE=DATE:20260711
SUMMARY:ASTELLAS APPROVAL: PADCEV
DESCRIPTION:Approved 2026-07-10: PADCEV (BLA761137 SUPPL37)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=761137\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761137
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:4892c7333ebf238018d5@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260709
DTEND;VALUE=DATE:20260710
SUMMARY:JHPCY CRL: SHR- 1210 injection
DESCRIPTION:CRL 2026-07-09: Jiangsu Hengrui Pharmaceuticals Co.\, Ltd. BLA 
 761308 (SHR- 1210 injection)\nConfidence: confirmed\nTicker JHPCY (confide
 nce 0.6)\nSource: https://download.open.fda.gov/crl/CRL_BLA761308_20260709
 _Redacted.pdf\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_BLA761308_20260709_Redacted.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:d77f5fc4bbb0f1f8facd@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260709
DTEND;VALUE=DATE:20260710
SUMMARY:Elevar Therapeutics Inc. CRL: rivoceranib tablet
DESCRIPTION:CRL 2026-07-09: Elevar Therapeutics Inc. NDA 216586 (rivocerani
 b tablet)\nConfidence: confirmed\nSource: https://download.open.fda.gov/cr
 l/CRL_NDA216586_20260709_Redacted.pdf\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_NDA216586_20260709_Redacted.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:4a7da7d6e45e382d081a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260709
DTEND;VALUE=DATE:20260710
SUMMARY:AMRX APPROVAL: SODIUM BICARBONATE
DESCRIPTION:Approved 2026-07-09: SODIUM BICARBONATE (NDA220790 ORIG1)\nConf
 idence: confirmed\nTicker AMRX (confidence 0.9)\nSource: https://www.acces
 sdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220
 790\nScheduling/reference data from public records\; dates can move. Not i
 nvestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220790
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:abd8e578e95d7da066c2@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260709
DTEND;VALUE=DATE:20260710
SUMMARY:SNY APPROVAL: SARCLISA ESCENA
DESCRIPTION:Approved 2026-07-09: SARCLISA ESCENA (BLA761445 ORIG1)\nConfide
 nce: confirmed\nTicker SNY (confidence 0.6)\nSource: https://www.accessdat
 a.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761445\
 nScheduling/reference data from public records\; dates can move. Not inves
 tment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761445
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:2a6331d86fe24ca18a53@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260707
DTEND;VALUE=DATE:20260708
SUMMARY:GLENMARK SPECLT APPROVAL: RYALTRIS
DESCRIPTION:Approved 2026-07-07: RYALTRIS (NDA211746 SUPPL11)\nConfidence: 
 confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.c
 fm?event=overview.process&ApplNo=211746\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=211746
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:65257fb992e508f52b0c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260707
DTEND;VALUE=DATE:20260708
SUMMARY:VERA APPROVAL: TRUTAKNA
DESCRIPTION:Approved 2026-07-07: TRUTAKNA (BLA761486 ORIG1)\nConfidence: co
 nfirmed\nTicker VERA (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761486\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761486
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:6554d3cef483970db284@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260702
DTEND;VALUE=DATE:20260703
SUMMARY:Ascelia Pharma AB CRL: (PN) (manganese chloride tetrahydrate — po
 wder for oral solution)
DESCRIPTION:CRL 2026-07-02: Ascelia Pharma AB NDA 220544 ((PN) (manganese c
 hloride tetrahydrate — powder for oral solution))\nConfidence: confirmed
 \nSource: https://download.open.fda.gov/crl/CRL_NDA220544_20260702_Redacte
 d.pdf\nScheduling/reference data from public records\; dates can move. Not
  investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_NDA220544_20260702_Redacted.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:5c64100dcbf95854296b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260701
DTEND;VALUE=DATE:20260702
SUMMARY:NVS APPROVAL: KISQALI FEMARA CO-PACK (COPACKAGED)
DESCRIPTION:Approved 2026-07-01: KISQALI FEMARA CO-PACK (COPACKAGED) (NDA20
 9935 SUPPL33)\nConfidence: confirmed\nTicker NVS (confidence 0.9)\nSource:
  https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.
 process&ApplNo=209935\nScheduling/reference data from public records\; dat
 es can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=209935
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:db040a8bf9aed5580703@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260701
DTEND;VALUE=DATE:20260702
SUMMARY:NVS APPROVAL: KISQALI
DESCRIPTION:Approved 2026-07-01: KISQALI (NDA209092 SUPPL27)\nConfidence: c
 onfirmed\nTicker NVS (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=209092
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:fc848ef511675e5bc48d@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260701
DTEND;VALUE=DATE:20260702
SUMMARY:IMNM PDUFA (company-disclosed): varegacestat
DESCRIPTION:PDUFA July 2026 - Immunome Inc. (varegacestat)\nConfidence: com
 pany-disclosed\nDate precision: month (shown on the first day)\nTicker IMN
 M (confidence 1.0)\nSource: https://www.sec.gov/Archives/edgar/data/147201
 2/000119312526453556/imnm-ex99_1.htm\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1472012/000119312526453556/imnm
 -ex99_1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:ddbc00417a75f90ee173@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260701
DTEND;VALUE=DATE:20260702
SUMMARY:RARE PDUFA (company-disclosed): PDUFA second half of 2026 - Ultrage
 nyx Pharmaceutical Inc.
DESCRIPTION:PDUFA second half of 2026 - Ultragenyx Pharmaceutical Inc.\nCon
 fidence: company-disclosed\nDate precision: half (shown on the first day)\
 nTicker RARE (confidence 1.0)\nSource: https://www.sec.gov/Archives/edgar/
 data/1515673/000119312526332802/rare-ex99_1.htm\nScheduling/reference data
  from public records\; dates can move. Not investment\, legal or medical a
 dvice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/rare
 -ex99_1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:435c26f8a99be80586f6@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260629
DTEND;VALUE=DATE:20260630
SUMMARY:UNCY CRL: oxylanthanum carbonate tablets
DESCRIPTION:CRL 2026-06-29: Unicycive Therapeutics Inc. NDA 218607 (oxylant
 hanum carbonate tablets)\nConfidence: confirmed\nTicker UNCY (confidence 0
 .9)\nSource: https://download.open.fda.gov/crl/CRL_NDA218607_20260629.pdf\
 nScheduling/reference data from public records\; dates can move. Not inves
 tment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_NDA218607_20260629.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:82934f0d198300ccb174@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260629
DTEND;VALUE=DATE:20260630
SUMMARY:Ipsen Biopharm Ltd. CRL: relabotulinumtoxin A injection
DESCRIPTION:CRL 2026-06-29: Ipsen Biopharm Ltd. BLA 761311 (relabotulinumto
 xin A injection)\nConfidence: confirmed\nSource: https://download.open.fda
 .gov/crl/CRL_BLA761311_20260629_Redacted.pdf\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_BLA761311_20260629_Redacted.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:9ab8ca2d61b7b7f8e5d2@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260629
DTEND;VALUE=DATE:20260630
SUMMARY:ARQT APPROVAL: ZORYVE
DESCRIPTION:Approved 2026-06-29: ZORYVE (NDA215985 SUPPL15)\nConfidence: co
 nfirmed\nTicker ARQT (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215985\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215985
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:72432af4aed2945e88e6@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260626
DTEND;VALUE=DATE:20260627
SUMMARY:Evergreen Theragnostics\, Inc. CRL: the Preparation of Gallium Ga E
 dotreotide Injection
DESCRIPTION:CRL 2026-06-26: Evergreen Theragnostics\, Inc. NDA 216900 (the 
 Preparation of Gallium Ga Edotreotide Injection)\nConfidence: confirmed\nS
 ource: https://download.open.fda.gov/crl/CRL_NDA216900_20260626_Redacted.p
 df\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_NDA216900_20260626_Redacted.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:d2d00a388d3963e704b7@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260626
DTEND;VALUE=DATE:20260627
SUMMARY:Swedish Orphan Biovitrum AB (publ) CRL: sirolimus for injectable su
 spension
DESCRIPTION:CRL 2026-06-26: Swedish Orphan Biovitrum AB (publ) BLA 761438 (
 sirolimus for injectable suspension)\nConfidence: confirmed\nSource: https
 ://download.open.fda.gov/crl/CRL_BLA761438_20260626_Redacted.pdf\nScheduli
 ng/reference data from public records\; dates can move. Not investment\, l
 egal or medical advice.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_BLA761438_20260626_Redacted.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:87debdbaea9783d9940e@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260626
DTEND;VALUE=DATE:20260627
SUMMARY:DECIPHERA PHARMS APPROVAL: ROMVIMZA
DESCRIPTION:Approved 2026-06-26: ROMVIMZA (NDA219304 SUPPL2)\nConfidence: c
 onfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cf
 m?event=overview.process&ApplNo=219304\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=219304
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:8e78e703cfad0a52fc2f@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260626
DTEND;VALUE=DATE:20260627
SUMMARY:VRDN APPROVAL: LUMVOA
DESCRIPTION:Approved 2026-06-26: LUMVOA (BLA761530 ORIG1)\nConfidence: conf
 irmed\nTicker VRDN (confidence 0.6)\nSource: https://www.accessdata.fda.go
 v/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761530\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761530
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:065bf5fb095e08945760@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260626
DTEND;VALUE=DATE:20260627
SUMMARY:ABBV APPROVAL: SKYRIZI
DESCRIPTION:Approved 2026-06-26: SKYRIZI (BLA761105 SUPPL45)\nConfidence: c
 onfirmed\nTicker ABBV (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761105\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761105
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:e673438fcedb15d566a0@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260625
DTEND;VALUE=DATE:20260626
SUMMARY:MERZ PHARMS APPROVAL: Xeomin
DESCRIPTION:Approved 2026-06-25: Xeomin (BLA125360 SUPPL108)\nConfidence: c
 onfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cf
 m?event=overview.process&ApplNo=125360\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=125360
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:f6f8ac2744c36ffd36a9@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260624
DTEND;VALUE=DATE:20260625
SUMMARY:AVYXA HOLDINGS APPROVAL: NAVITRUX
DESCRIPTION:Approved 2026-06-24: NAVITRUX (NDA220436 ORIG1)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=220436\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220436
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:4dbc642f10a567472458@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260624
DTEND;VALUE=DATE:20260625
SUMMARY:PFE APPROVAL: IBRANCE
DESCRIPTION:Approved 2026-06-24: IBRANCE (NDA207103 SUPPL24)\nConfidence: c
 onfirmed\nTicker PFE (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=207103
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:618657e9bd95e4cf0024@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260624
DTEND;VALUE=DATE:20260625
SUMMARY:MRK APPROVAL: KEYTRUDA
DESCRIPTION:Approved 2026-06-24: KEYTRUDA (BLA125514 SUPPL187)\nConfidence:
  confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=125514
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:c565fa7a8ac72ec0b1a7@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260624
DTEND;VALUE=DATE:20260625
SUMMARY:PFE APPROVAL: IBRANCE
DESCRIPTION:Approved 2026-06-24: IBRANCE (NDA212436 SUPPL12)\nConfidence: c
 onfirmed\nTicker PFE (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212436\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=212436
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:a34eee5dc0758d8a9002@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260624
DTEND;VALUE=DATE:20260625
SUMMARY:MRK APPROVAL: KEYTRUDA QLEX
DESCRIPTION:Approved 2026-06-24: KEYTRUDA QLEX (BLA761467 SUPPL4)\nConfiden
 ce: confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata
 .fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761467\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761467
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:75b34c8f73a4d0ad1e10@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260624
DTEND;VALUE=DATE:20260625
SUMMARY:IONS APPROVAL: TRYNGOLZA (AUTOINJECTOR)
DESCRIPTION:Approved 2026-06-24: TRYNGOLZA (AUTOINJECTOR) (NDA218614 SUPPL4
 )\nConfidence: confirmed\nTicker IONS (confidence 0.6)\nSource: https://ww
 w.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&App
 lNo=218614\nScheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218614
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:c3a7d3407a51359656a8@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260624
DTEND;VALUE=DATE:20260625
SUMMARY:IMMUNOMEDICS INC APPROVAL: TRODELVY
DESCRIPTION:Approved 2026-06-24: TRODELVY (BLA761115 SUPPL64)\nConfidence: 
 confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.c
 fm?event=overview.process&ApplNo=761115\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761115
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:371a652b58902e0db2d2@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260624
DTEND;VALUE=DATE:20260625
SUMMARY:IMMUNOMEDICS INC APPROVAL: TRODELVY
DESCRIPTION:Approved 2026-06-24: TRODELVY (BLA761115 SUPPL63)\nConfidence: 
 confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.c
 fm?event=overview.process&ApplNo=761115\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761115
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:c4afb16ed19a726772ae@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260623
DTEND;VALUE=DATE:20260624
SUMMARY:Tanvex BioPharma USA\, Inc. CRL: CRL 2026-06-23: Tanvex BioPharma U
 SA\, Inc. BLA 761266
DESCRIPTION:CRL 2026-06-23: Tanvex BioPharma USA\, Inc. BLA 761266\nConfide
 nce: confirmed\nSource: https://download.open.fda.gov/crl/CRL_BLA761266_20
 260623_Redacted.pdf\nScheduling/reference data from public records\; dates
  can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_BLA761266_20260623_Redacted.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:80e72e84c713f976fb15@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260620
DTEND;VALUE=DATE:20260621
SUMMARY:QUIT CRL: cytisinicline tablet\, ©
DESCRIPTION:CRL 2026-06-20: Achieve Life Sciences\, Inc. NDA 218995 (cytisi
 nicline tablet\, ©)\nConfidence: confirmed\nTicker QUIT (confidence 0.9)\
 nSource: https://download.open.fda.gov/crl/CRL_NDA218995_20260620_Redacted
 .pdf\nScheduling/reference data from public records\; dates can move. Not 
 investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_NDA218995_20260620_Redacted.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:20378fbe6da40e5840fe@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260618
DTEND;VALUE=DATE:20260619
SUMMARY:ADCOM (scheduled): AdCom 2026-06-18: Vaccines and Related Biologica
 l Products Advisory Committee
DESCRIPTION:AdCom 2026-06-18: Vaccines and Related Biological Products Advi
 sory Committee\nConfidence: scheduled\nSource: https://www.federalregister
 .gov/documents/2026/05/22/2026-10321/vaccines-and-related-biological-produ
 cts-advisory-committee-notice-of-meeting-establishment-of-a\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://www.federalregister.gov/documents/2026/05/22/2026-10321/vaccine
 s-and-related-biological-products-advisory-committee-notice-of-meeting-est
 ablishment-of-a
CATEGORIES:adcom,scheduled
END:VEVENT
BEGIN:VEVENT
UID:7c9a413abbc6885198c8@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260618
DTEND;VALUE=DATE:20260619
SUMMARY:ZEAL.CO APPROVAL: ZEGALOGUE\; ZEGALOGUE (AUTOINJECTOR)
DESCRIPTION:Approved 2026-06-18: ZEGALOGUE\; ZEGALOGUE (AUTOINJECTOR) (NDA2
 14231 SUPPL4)\nConfidence: confirmed\nTicker ZEAL.CO (confidence 0.95)\nSo
 urce: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=over
 view.process&ApplNo=214231\nScheduling/reference data from public records\
 ; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=214231
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:a7925e0bf5aba334682a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260617
DTEND;VALUE=DATE:20260618
SUMMARY:Avyxa Holdings\, LLC CRL: Cisplatin Injection
DESCRIPTION:CRL 2026-06-17: Avyxa Holdings\, LLC NDA 220748 (Cisplatin Inje
 ction)\nConfidence: confirmed\nSource: https://download.open.fda.gov/crl/C
 RL_NDA220748_20260617.pdf\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_NDA220748_20260617.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:e36067cac6c61abd21f0@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260617
DTEND;VALUE=DATE:20260618
SUMMARY:GLAXOSMITHKLINE APPROVAL: UTEBZI
DESCRIPTION:Approved 2026-06-17: UTEBZI (NDA215960 ORIG1)\nConfidence: conf
 irmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?e
 vent=overview.process&ApplNo=215960\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215960
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:c886b73d5453719bcbc3@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260616
DTEND;VALUE=DATE:20260617
SUMMARY:AZURITY APPROVAL: APREPITANT
DESCRIPTION:Approved 2026-06-16: APREPITANT (NDA218754 ORIG1)\nConfidence: 
 confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.c
 fm?event=overview.process&ApplNo=218754\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218754
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:1df45731ab815cbfc6d1@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260616
DTEND;VALUE=DATE:20260617
SUMMARY:AMPH APPROVAL: REXTOVY
DESCRIPTION:Approved 2026-06-16: REXTOVY (NDA208969 SUPPL2)\nConfidence: co
 nfirmed\nTicker AMPH (confidence 0.6)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208969\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=208969
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:06f9620eb2e040a1e0be@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260615
DTEND;VALUE=DATE:20260616
SUMMARY:Tris Pharma\, Inc. CRL: oxybate for extended-release powder for ora
 l suspension (oxybate ER OS)
DESCRIPTION:CRL 2026-06-15: Tris Pharma\, Inc. NDA 220138 (oxybate for exte
 nded-release powder for oral suspension (oxybate ER OS))\nConfidence: conf
 irmed\nSource: https://download.open.fda.gov/crl/CRL_NDA220138_20260615_Re
 dacted.pdf\nScheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_NDA220138_20260615_Redacted.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:bcdd327c34bd8147333b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260612
DTEND;VALUE=DATE:20260613
SUMMARY:PROVENTION BIO INC APPROVAL: TZIELD
DESCRIPTION:Approved 2026-06-12: TZIELD (BLA761183 SUPPL10)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=761183\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761183
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:b666c9183b939f527cf8@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260612
DTEND;VALUE=DATE:20260613
SUMMARY:MRK APPROVAL: WELIREG
DESCRIPTION:Approved 2026-06-12: WELIREG (NDA215383 SUPPL15)\nConfidence: c
 onfirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215383\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215383
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:897ca66b05ba98af9730@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260612
DTEND;VALUE=DATE:20260613
SUMMARY:MRK APPROVAL: KEYTRUDA
DESCRIPTION:Approved 2026-06-12: KEYTRUDA (BLA125514 SUPPL192)\nConfidence:
  confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=125514
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:5f19dc43526498f4bcf9@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260612
DTEND;VALUE=DATE:20260613
SUMMARY:MRK APPROVAL: KEYTRUDA QLEX
DESCRIPTION:Approved 2026-06-12: KEYTRUDA QLEX (BLA761467 SUPPL9)\nConfiden
 ce: confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata
 .fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761467\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761467
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:8c9061c4744b4bcffe3f@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260612
DTEND;VALUE=DATE:20260613
SUMMARY:BAYER HEALTHCARE APPROVAL: AMBELVIST
DESCRIPTION:Approved 2026-06-12: AMBELVIST (NDA219627 ORIG1)\nConfidence: c
 onfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cf
 m?event=overview.process&ApplNo=219627\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=219627
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:f8b906b24898eba9e353@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260612
DTEND;VALUE=DATE:20260613
SUMMARY:ABBV APPROVAL: SKYRIZI
DESCRIPTION:Approved 2026-06-12: SKYRIZI (BLA761105 SUPPL44)\nConfidence: c
 onfirmed\nTicker ABBV (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761105\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761105
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:9445dd3696800e30640a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260612
DTEND;VALUE=DATE:20260613
SUMMARY:AZN APPROVAL: TRUQAP
DESCRIPTION:Approved 2026-06-12: TRUQAP (NDA218197 SUPPL4)\nConfidence: con
 firmed\nTicker AZN (confidence 0.9)\nSource: https://www.accessdata.fda.go
 v/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218197
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:f2f907017b894616e4e0@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260611
DTEND;VALUE=DATE:20260612
SUMMARY:HOFFMANN-LA ROCHE APPROVAL: ALECENSA
DESCRIPTION:Approved 2026-06-11: ALECENSA (NDA208434 SUPPL16)\nConfidence: 
 confirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.c
 fm?event=overview.process&ApplNo=208434\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=208434
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:9a33dde747e12860d99d@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260610
DTEND;VALUE=DATE:20260611
SUMMARY:Bridge Regulatory Affairs\, LLC CRL: octreotide hydrochloride exten
 ded- release injection
DESCRIPTION:CRL 2026-06-10: Bridge Regulatory Affairs\, LLC NDA 218600 (oct
 reotide hydrochloride extended- release injection)\nConfidence: confirmed\
 nSource: https://download.open.fda.gov/crl/CRL_NDA218600_20260610_Redacted
 .pdf\nScheduling/reference data from public records\; dates can move. Not 
 investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_NDA218600_20260610_Redacted.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:84745ed7870becb91130@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260609
DTEND;VALUE=DATE:20260610
SUMMARY:LLY APPROVAL: EBGLYSS
DESCRIPTION:Approved 2026-06-09: EBGLYSS (BLA761306 SUPPL6)\nConfidence: co
 nfirmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761306\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761306
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:7a56c94d3cbc34c3fd7b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260605
DTEND;VALUE=DATE:20260606
SUMMARY:PFE APPROVAL: HYMPAVZI
DESCRIPTION:Approved 2026-06-05: HYMPAVZI (BLA761369 SUPPL3)\nConfidence: c
 onfirmed\nTicker PFE (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761369\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761369
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:bb62946437aea2e9f2c3@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260604
DTEND;VALUE=DATE:20260605
SUMMARY:Xspray Pharma AB CRL: (9) (nilotinib) capsules
DESCRIPTION:CRL 2026-06-04: Xspray Pharma AB NDA 217644 ((9) (nilotinib) ca
 psules)\nConfidence: confirmed\nSource: https://download.open.fda.gov/crl/
 CRL_NDA217644_20260604_Redacted.pdf\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_NDA217644_20260604_Redacted.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:13c341f2ad345e416dad@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260602
DTEND;VALUE=DATE:20260603
SUMMARY:CASPER PHARMA LLC APPROVAL: TIOCYSTIN
DESCRIPTION:Approved 2026-06-02: TIOCYSTIN (NDA212927 ORIG1)\nConfidence: c
 onfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cf
 m?event=overview.process&ApplNo=212927\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=212927
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:66694ef2e041f353f8f1@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260602
DTEND;VALUE=DATE:20260603
SUMMARY:LUPIN LIMITED APPROVAL: RANLUSPEC
DESCRIPTION:Approved 2026-06-02: RANLUSPEC (BLA761480 ORIG1)\nConfidence: c
 onfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cf
 m?event=overview.process&ApplNo=761480\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761480
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:e129d9b82e745be9d6ce@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260529
DTEND;VALUE=DATE:20260530
SUMMARY:CING CRL: dexmethylphenidate hydrochloride extended-release tablets
DESCRIPTION:CRL 2026-05-29: Cingulate Therapeutics\, LLC NDA 220283 (dexmet
 hylphenidate hydrochloride extended-release tablets)\nConfidence: confirme
 d\nTicker CING (confidence 0.9)\nSource: https://download.open.fda.gov/crl
 /CRL_NDA220283_20260529_Redacted.pdf\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://download.open.fda.gov/crl/CRL_NDA220283_20260529_Redacted.pdf
CATEGORIES:crl,confirmed
END:VEVENT
BEGIN:VEVENT
UID:1b5db9b5873c6cf7678a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260529
DTEND;VALUE=DATE:20260530
SUMMARY:SHIONOGI APPROVAL: XOCOVA
DESCRIPTION:Approved 2026-05-29: XOCOVA (NDA220442 ORIG1)\nConfidence: conf
 irmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?e
 vent=overview.process&ApplNo=220442\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220442
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:f0c527a0be37c882a7c1@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260529
DTEND;VALUE=DATE:20260530
SUMMARY:HAISCO APPROVAL: CYPSEDO
DESCRIPTION:Approved 2026-05-29: CYPSEDO (NDA220482 ORIG1)\nConfidence: con
 firmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?
 event=overview.process&ApplNo=220482\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220482
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:3f7b8b649b226574d0ee@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260529
DTEND;VALUE=DATE:20260530
SUMMARY:WOCKHARDT BIO AG APPROVAL: ZAYNICH
DESCRIPTION:Approved 2026-05-29: ZAYNICH (NDA220787 ORIG1)\nConfidence: con
 firmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?
 event=overview.process&ApplNo=220787\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220787
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:1398e78a61df49b5df5c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260529
DTEND;VALUE=DATE:20260530
SUMMARY:MNKD APPROVAL: AFREZZA
DESCRIPTION:Approved 2026-05-29: AFREZZA (BLA022472 SUPPL29)\nConfidence: c
 onfirmed\nTicker MNKD (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022472\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=022472
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:be7441e71870e2786bfd@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260529
DTEND;VALUE=DATE:20260530
SUMMARY:CYCLE APPROVAL: CAVHANZA
DESCRIPTION:Approved 2026-05-29: CAVHANZA (NDA217379 ORIG1)\nConfidence: co
 nfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
 ?event=overview.process&ApplNo=217379\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=217379
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:b35f9769b8185f12678b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260528
DTEND;VALUE=DATE:20260529
SUMMARY:ADCOM (scheduled): AdCom 2026-05-28: Vaccines and Related Biologica
 l Products Advisory Committee
DESCRIPTION:AdCom 2026-05-28: Vaccines and Related Biological Products Advi
 sory Committee\nConfidence: scheduled\nSource: https://www.federalregister
 .gov/documents/2026/04/27/2026-08122/vaccines-and-related-biological-produ
 cts-advisory-committee-notice-of-meeting-establishment-of-a\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://www.federalregister.gov/documents/2026/04/27/2026-08122/vaccine
 s-and-related-biological-products-advisory-committee-notice-of-meeting-est
 ablishment-of-a
CATEGORIES:adcom,scheduled
END:VEVENT
BEGIN:VEVENT
UID:7670fa53c5c1538aa6cb@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260528
DTEND;VALUE=DATE:20260529
SUMMARY:JANSSEN BIOTECH APPROVAL: TREMFYA
DESCRIPTION:Approved 2026-05-28: TREMFYA (BLA761061 SUPPL34)\nConfidence: c
 onfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cf
 m?event=overview.process&ApplNo=761061\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761061
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:81f18cfee64b7d4bf1bf@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260528
DTEND;VALUE=DATE:20260529
SUMMARY:AZN APPROVAL: IMFINZI
DESCRIPTION:Approved 2026-05-28: IMFINZI (BLA761069 SUPPL53)\nConfidence: c
 onfirmed\nTicker AZN (confidence 0.6)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761069
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:ccb5086da2f9bff3389a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260527
DTEND;VALUE=DATE:20260528
SUMMARY:ABBV APPROVAL: DECNUPAZ
DESCRIPTION:Approved 2026-05-27: DECNUPAZ (BLA761460 ORIG1)\nConfidence: co
 nfirmed\nTicker ABBV (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761460\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761460
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:1cac484a555aca2b1eb8@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260523
DTEND;VALUE=DATE:20260524
SUMMARY:ACTELION APPROVAL: UPTRAVI
DESCRIPTION:Approved 2026-05-23: UPTRAVI (NDA207947 SUPPL14)\nConfidence: c
 onfirmed\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.cf
 m?event=overview.process&ApplNo=207947\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=207947
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
